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Summary. The ability to predict individualized treatment effects (ITEs) based on a given
patient’s profile is essential for personalized medicine. The prediction of ITEs enables the
comparison of the effectiveness of two treatment procedures for a specific individual. We
propose a hypothesis testing approach to choosing between two available treatments for a
given individual in the framework of high-dimensional linear models. The methodological
novelty is the development of a testing procedure with the type-I error uniformly controlled
for any future high-dimensional observation, while the existing methods can only handle
certain specific forms of covariates observation. The procedure is based on a debiased
estimator of the ITEs and its asymptotic normality. The asymptotic power of the proposed
test is established and the finite sample performance is demonstrated in simulation stud-
ies. We introduce the optimality framework of hypothesis testing in high dimensions from
both minimaxity and adaptivity perspectives and establish the optimality of the proposed
procedure. The proposed method can be extended to conduct statistical inference for gen-
eral linear contrasts, including both average treatment effect and the prediction problem.
The procedure is further illustrated through an analysis of electronic health records data
from patients with rheumatoid arthritis.
Keywords: Electronic Health Records; Personalized Medicine; Prediction; General
Linear Contrasts; Confidence Intervals; Bias Correction.
1. Introduction
It has been well recognized that the effectiveness and potential risk of a treatment often
vary significantly by patient subgroups. The ability to predict individualized treatment
effects (ITEs) based on a given covariate profile is essential for precision medicine. Al-
though trial-and-error and one-size-fits-all approaches remain a common practice, much
recent focus has been placed on predicting treatment effects at a more individual level
[La Thangue and Kerr, 2011, Ong et al., 2012]. Genetic mutations and gene-expression
profiles are increasingly used to guide treatment selection for cancer patients [Albain
et al., 2010, Eberhard et al., 2005]. Large scale clinical trials are being conducted to
evaluate individualized treatment strategies [Chantrill et al., 2015, Evans and Relling,
2004, Simon et al., 2007]. The increasing availability of electronic health records (EHR)
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systems with detailed patient data promises a new paradigm for translational precision
medicine research. Models for predicting ITE can be estimated using real world data
and can potentially be deployed more efficiently to clinical practice.
Motivated by the ITE estimation using EHR data with high-dimensional covariates,
we consider in this paper efficient estimation and inference procedures for predicting a
future patient’s ITE given his/her p dimensional covariates when p is potentially much
larger than the sample size n. Specifically, we consider high-dimensional linear regression
models for the outcomes in the two treatment groups:
Yk = Xkβk + k, k = 1, 2, (1)
where Yk = (yk,1, ..., yk,nk)
ᵀ and Xk = (Xk,1, ...,Xk,nk)ᵀ are the response and covariates
observed independently for the nk subjects in the treatment group k respectively, k =
(k,1, ..., k,nk)
ᵀ is the error vector independent of Xk with constant variance σ2k = var(k,i)
and βk ∈ Rp is the regression vector for the kth treatment group. For a given patient
with covariate vector xnew, we consider testing the hypothesis
H0 : x
ᵀ
new
(β1 − β2) ≤ 0 vs. H1 : xᵀnew(β1 − β2) > 0. (2)
A novel procedure, High-dimensional Individualized Treatment Selection (HITS), is de-
veloped for testing the hypothesis (2). In addition, we construct point and interval
estimators for the ITE ∆new = x
ᵀ
new
(β1 − β2). The HITS method, while motivated by in-
ference for ITE, can be also be used to make inference in other related problems including
the average treatment effect (ATE) with xnew chosen as the average of the covariates and
prediction such as xᵀ
new
β1. See Sections 2.4 and 5 for more detailed discussion on these
related problems.
In the following, we first describe our motivating example for Individualized Treat-
ment Selection problem in Section 1.1 and then detail the statistical contributions of the
current paper and comparison with literature results in Section 1.2 and 1.3, respectively.
1.1. Individualized Treatment Selection
While clinical trials and traditional cohort studies remain critical sources for precision
medicine research, they have limitations including the generalizability of study findings
and the limited ability to test broader hypotheses. In recent years, due to the increasing
adoption of EHR and the linkage of EHR with bio-repositories and other research reg-
istries, integrated large datasets now exist as a new source for precision medicine studies.
For example, the Partner’s Healthcare System (PHS) biobank contains both a wealth
of clinical (e.g. diagnoses, treatments, laboratory values) and biological measurements
including genomic data [Gainer et al., 2016]. These integrated datasets open opportu-
nities for developing EHR-based individualized treatment selection models, which can
potentially be fed back to the EHR system for guiding clinical decision making.
To enable EHR for such precision medicine research, different patients cohorts with
specific diseases of interest have been constructed at PHS via the efforts of the Informat-
ics for Integrating Biology and the Bedside (i2b2) [Kohane et al., 2012]. An example of
such disease cohort is rheumatoid arthritis (RA), consisting of 4453 patients identified
as having RA using a machine learning algorithm [Liao et al., 2010]. A small subset
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of these patients have their genetic and biological markers measured. The biomarker
data integrated with EHR data can be used to derive ITE models for guiding treat-
ment strategies for RA patients. A range of disease modifying treatment options are
now available for RA patients, including methotrexate, tumor necrosis factor inhibitors
often referred to as anti-TNF, and the combination of the two [Calabrese et al., 2016].
The superiority of the combination therapy over monotherapy has been well established
[Emery et al., 2008, Breedveld et al., 2006, van der Heijde et al., 2006]. Despite its su-
periority, a significant proportion of patients do not respond to the combination therapy
with reported response rates ranging from about 30% to 60%. Due to the high cost
and significant side effects including serious infection and malignancy associated with
anti-TNF therapy [Bongartz et al., 2006], there is a pressing need to develop ITE models
to guide RA treatment selection. We propose to address this need by deriving an ITE
model for RA using the biomarker linked EHR data at PHS. Our proposed high dimen-
sional ITE inference procedures are desirable tools for application since the number of
potential predictors is large in this setting.
1.2. Statistical Framework and Contributions
Many statistical and machine learning algorithms have been proposed for estimating the
ITEs [Zhou et al., 2017, Zhao et al., 2012, Imai and Ratkovic, 2013, Qian and Murphy,
2011]. However, existing methods largely focused on the low-dimensional settings. In
the presence of high dimensional predictors, inference for the ITEs becomes significantly
more challenging. Several regularized regression procedures can be used to obtain point
estimators for ∆new = x
ᵀ
new
(β1 − β2) [Chen et al., 2001, Tibshirani, 1996, Fan and Li,
2001, Cande`s and Tao, 2007, Sun and Zhang, 2012, Zhang, 2010, Belloni et al., 2011,
Moon et al., 2007, Song et al., 2015, Belloni et al., 2014]. However, when the goal is
to construct confidence intervals (CIs) for ∆new, it is problematic to estimate ∆new by
simply plugging in these regularized estimators due to their inherent biases. These
regularization methods tend to shrink small coefficients to zero and produce biased
estimates for large coefficients. These biases can accumulate when projecting along the
direction of xnew and result in a significant bias in ∆new. Statistically, the bias-variance
tradeoff for estimating the ITE ∆new is fundamentally different from that for estimating
the regression vectors β1 and β2.
In this paper, we develop the novel HITS method that aims to choose between two
treatments for a given individual based on the observed high-dimensional covariates.
Statistically, we construct CIs and carry out hypothesis test for ∆new under the chal-
lenging setting where xnew is of high-dimension and of no special structure. Rigorous
justifications for the inference procedures are given. It is shown that the test controls
the type-I error. The power of the test as well as the coverage and length properties of
the CIs are analyzed.
An optimality framework for hypothesis testing in the high-dimensional sparse linear
model is introduced and the optimality of the proposed HITS method is established.
The optimality framework is from two perspectives, minimaxity and adaptivity, where
minimaxity captures the difficulty of the testing problem with true sparsity level known
a priori and adaptivity captures a more challenging problem with respect to unknown
sparsity. It is shown that the proposed HITS method is an optimal testing procedure
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for problem (2) over various types of loadings xnew in practical settings where the exact
sparsity level is unknown. In a more general framework, the developed methods can be
used to tackle the statistical inference for the linear contrasts xᵀ
new
(β1 − β2) and xᵀnewβk
for k = 1, 2. As recognized in the literature [Cai and Guo, 2017, Athey et al., 2018,
Zhu and Bradic, 2018], constructing a unified inference procedure for linear contrasts in
high-dimensional regression with no restriction on the loading vector xnew is extremely
challenging. A more detailed discussion on the challenges of inference for general linear
contrasts is given in Sections 4.3 and 8.
The main contribution of the current paper is two-fold,
1. We propose a novel calibration method for the plug-in estimators such that the
proposed HITS estimator has an asymptotic normal distribution for any given xnew.
This is achieved by imposing an additional constraint in the construction of the
projection direction for bias correction to guarantee that the variance of the HITS
estimator dominates its bias for any xnew. This additional constraint restricts the
feasible set in one more direction and automatically enables a unified inference
procedure for an arbitrary xnew. See Figure 3 for illustration of the effect of this
additional constraint. To the best of our knowledge, the proposed method is the first
unified inference procedure with theoretical guarantee for general linear contrasts
xᵀ
new
(β1 − β2) and xᵀnewβk for k = 1, 2, where the high-dimensional loading xnew is of
no special structure.
2. An optimality framework is introduced from both the minimaxity and adaptivity
perspectives. In particular, adaptivity results for hypothesis testing in high dimen-
sions are obtained. It is shown that the proposed HITS method is optimal over
different types of loadings, including both exact loadings and decaying loadings de-
fined in Section 4.1. A novel technical tool, transferring technique, is developed to
establish rate-optimal lower bound result. This tool can be of independent interest.
1.3. Comparison with High-dimensional Inference Literature
For a single regression coefficient under sparse linear models, Zhang and Zhang [2014],
van de Geer et al. [2014], Javanmard and Montanari [2014] introduced the bias correc-
tion method for CI construction. Inference for more general linear contrasts has been
investigated recently in Cai and Guo [2017], Athey et al. [2018], Zhu and Bradic [2018].
These all require special structure on the loading xnew. It is still unknown prior to the
current work how to make inference for all loadings xnew.
More specifically, in the context of constructing CIs, Cai and Guo [2017] showed
a significance difference between sparse and dense xnew. The methods developed for
a single regression coefficient can be extended to a sparse xnew but the construction
of a dense xnew relies on a conservative upper bound and requires the information on
sparsity level. Athey et al. [2018] constructed CI for the linear contrasts for xnew only
if the loading xnew has a bounded weighted `2 norm. Zhu and Bradic [2018] con-
structed a CI for the linear contrast under the condition that the conditional expectation
E
[
xᵀ
new
X1,i | vᵀ1X1,i, · · · ,vᵀp−1X1,i
]
is a sparse linear combination of vᵀ1X1,i, · · · ,vᵀp−1X1,i,
where {vj}1≤j≤p−1 span the space orthogonal to xnew. The most significant distinction of
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the proposed HITS method from the aforementioned literature is a unified uncertainty
quantification method for all high-dimensional loadings xnew.
Another intuitive inference method for a general linear contrast is to plug-in the
debiased estimator for individual regression coefficients developed in Zhang and Zhang
[2014], van de Geer et al. [2014], Javanmard and Montanari [2014]. A numerical com-
parison of this estimator with the proposed HITS procedure is given in Section 6. The
results show that HITS not only is computationally more efficient but also has uniformly
better coverage properties than the plug-in estimator.
From another perspective, we compare the optimality results for hypothesis testing
established here with those for CIs given in Cai and Guo [2017]. The adaptivity frame-
work for hypothesis testing is different from that for CI construction. In addition, the
current paper considers a broader classes of loadings than those in Cai and Guo [2017],
including the case of decaying loadings and a more general class of sparse exact loadings.
1.4. Organization of the Paper
The rest of the paper is organized as follows. In Section 2, we discuss the proposed
hypothesis testing and CI procedures for ∆new. Theoretical properties of the proposed
method are present in Section 3; Optimality of the hypothesis testing problem is dis-
cussed in Section 4; The proposed method is extended in Section 5 to quantify uncer-
tainty for the prediction problem in high dimensional linear regression; The numerical
performance of the proposed method is investigated in Section 6. In Section 7, we apply
the proposed method to infer about ITE of the aforementioned combination therapy
over methotrexate alone for treating RA using EHR data from PHS. Discussions are
provided in Section 8 and proofs of the main results are given in Section 9. Additional
discussions, simulations and proofs are present in the supplementary materials.
1.5. Notations
For a matrix X ∈ Rn×p, Xi·, X·j , and Xij denote respectively its ith row, jth column, and
(i, j) entry. For a vector x ∈ Rp, x−j denotes the subvector of x excluding the jth element,
supp(x) denotes the support of x and the `q norm of x is defined as ‖x‖q = (
∑p
j=1 |xj |q)
1
q
for q ≥ 0 with ‖x‖0 = |supp(x)| and ‖x‖∞ = max1≤j≤p |xj |. For a matrix A, we define
the spectral norm ‖A‖2 = sup‖x‖2=1 ‖Ax‖2; For a symmetric matrix A, λmin (A) and
λmax (A) denote respectively the smallest and largest eigenvalue of A. We use c and C
to denote generic positive constants that may vary from place to place. For two positive
sequences an and bn, an . bn means an ≤ Cbn for all n and an & bn if bn . an and
an  bn if an . bn and bn . an, and an  bn if limn→∞ anbn = 0 and an  bn if bn  an.
2. Methodology
In this section, we propose statistical inference procedures for the ITE ∆new = x
ᵀ
new
(β1 −
β2). We first discuss the bias correction method for estimating the high dimensional
regression parameter βk in Section 2.1 and introduce a novel construction of projection
direction xᵀ
new
βk which adapt to any given loading xnew in Section 2.2, where throughout
we use subscript k ∈ {1, 2} to index the treatment group. Then in Section 2.3, we
6 Cai, Cai & Guo
propose point and interval estimators as well as a hypothesis testing procedure for ∆new.
In Section 2.4, we extend the proposed method to inference for average treatment effect.
2.1. Idea of Bias Correction
Without loss of generality, we discuss the bias correction idea for estimating xᵀ
new
β1 and
the same approach can be extended to k = 2. With the observations Y1 ∈ Rn1 and
X1 ∈ Rn1×p, we may estimate B1 = (βᵀ1 , σ1)ᵀ as the scaled LASSO estimator
B̂1 =
(
β̂ᵀ1 , σ̂1
)ᵀ
= arg min
β1∈Rp,σ1∈R+
‖Y1 − X1β1‖22
2n1σ1
+
σ1
2
+
√
A log p
n1
p∑
j=1
W1,j |β1,j |, (3)
where A > 2 is the pre-specified tuning parameter and W1,j =
√
1
n1
∑n1
i=1X
2
k,ij is the
penalization weight of the jth variable. A natural and simple way to estimate xᵀnewβ1 is
to plug in the scaled LASSO estimator β̂1 in (3). However, this plug-in estimator x
ᵀ
newβ̂1
is known to suffer from the bias induced by the (scaled) LASSO method. For the special
case xnew = ej , where ej is the j
th Euclidean basis vector, various forms of bias-corrected
estimators have been introduced in Zhang and Zhang [2014], van de Geer et al. [2014],
Javanmard and Montanari [2014] to correct the bias of the plug-in estimator β̂1,j and
then construct CIs centered at the corresponding bias-corrected estimators. This bias-
correction idea can be generalized to general linear contrasts xᵀnewβ for certain class of
xnew, where a key step is to estimate the bias x
ᵀ
new(β̂1 − β1). To this end, we aim to
identify an effective projection direction û1 ∈ Rp to construct a debiased estimator for
xᵀ
new
β1 as
xᵀ
new
β̂1 + û
ᵀ
1Ê1, where Êk =
1
nk
nk∑
i=1
Xk,i
(
Yk,i −Xᵀk,iβ̂k
)
. (4)
The error decomposition of the above bias-corrected estimator is
(xᵀ
new
β̂1 + û
ᵀ
1Ê1)− xᵀnewβ1 = −uᵀ
1
n1
n1∑
i=1
X1,i1,i +
(
Σ̂1u− xnew
)ᵀ
(β̂1 − β1) (5)
where Σ̂k =
1
nk
∑nk
i=1 Xk,iX
ᵀ
k,i. As highlighted in Zhang and Zhang [2014], Javanmard
and Montanari [2014], Cai and Guo [2017], the key idea of constructing û1 is to find a
projection direction such that the variance of uᵀ 1n1
∑n1
i=1 X1,i1,i is minimized/controlled
while the bias component Σ̂1u − xnew is constrained. Specifically, this idea is imple-
mented in Cai and Guo [2017] via the following algorithm
u˜1 = arg min
u∈Rp
{
uᵀΣ̂1u :
∥∥∥Σ̂1u− xnew∥∥∥∞ ≤ ‖xnew‖2λ1} (6)
where λ1 
√
log p/n1. Note that the estimator in Athey et al. [2018] is of a similar
form as (6) but with some slight technical difference. We shall emphasize that the bias-
corrected estimator (4) with the projection direction u˜1 defined in (6) is only effective
for a small class of xnew. Specifically, Cai and Guo [2017] showed that u˜1 is effective for
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bias-correction if xnew is of certain sparse structure and Athey et al. [2018] showed that
the bias correction method is only effective if xnew is of a bounded weighted `2 norm. On
the other hand, as established in Proposition 2 in Section 8, if the loading xnew is of
certain dense structure, then u˜1 fails to correct the bias of the plug-in estimator. In next
section, we discuss a novel method of constructing projection directions that adapt to
arbitrary loading xnew. This construction of projection directions enables us to correct
the bias for an arbitrary loading xnew, regardless of the structure of xnew.
2.2. Construction of the Projection Direction
To effectively debias for an arbitrary xnew, we propose to identify the projection direction
ûk for the k
th treatment as
ûk = arg min
u∈Rp
uᵀΣ̂ku subject to
∥∥∥Σ̂ku− xnew∥∥∥∞ ≤ ‖xnew‖2λk (7)∣∣∣xᵀnewΣ̂ku− ‖xnew‖22∣∣∣ ≤ ‖xnew‖22λk, (8)
where λk 
√
log p/nk. Our proposed bias corrected estimator for x
ᵀ
new
βk is then
x̂ᵀnewβk = xᵀnewβ̂k + û
ᵀ
kÊk. (9)
The main difference between û1 and u˜1 in (6) is the additional constraint (8). A
general strategy developed in the bias correction literature [Zhang and Zhang, 2014,
Javanmard and Montanari, 2014, Cai and Guo, 2017] is to minimize the variance com-
ponent while constraining the bias. However, to develop a unified inference method for
all xnew, the optimization strategy developed in the current paper is a triplet, minimizing
the variance, constraining the bias and constraining the variance. In particular, the
additional constraint (8) is imposed to constrain the variance such that it is dominating
the bias component, which is essential for CI construction. Such a general optimiza-
tion strategy can be of independent interest and applied to other inference problems.
We call the construction defined in (7) and (8) for identifying the projection direction
“Variance-enhancement Projection Direction”.
An equivalent way of constructing the projection direction defined in (7) and (8) is,
ûk = arg min
u∈Rp
uᵀΣ̂ku subject to sup
w∈C
∣∣∣〈w, Σ̂ku− xnew〉∣∣∣ ≤ ‖xnew‖2λk (10)
where C =
{
e1, · · · , ep, 1‖xnew‖2xnew
}
with ei denoting the ith standard Euclidean basis
vector. The feasible set in (10) constrains that the projected values
〈
w, Σ̂u− xnew
〉
of
Σ̂ku−xnew to any of the p+ 1 vectors in C are small. In contrast, the existing debiased
procedures only constrain that the projected values to all the standard Euclidean basis
vectors, max1≤j≤p
∣∣∣〈ej , Σ̂u− xnew〉∣∣∣, are small, which is motivated from the decomposi-
tion (5) and the Ho¨lder’s inequality |(Σ̂1u−xnew)ᵀ(β̂1−β1)| ≤ ‖Σ̂1u−xnew‖∞‖β̂1−β1‖1.
In the case where xnew is of complicated structures, the idea motivated from (5) is not
effective. However, this newly proposed projection direction defined in (10) resolves the
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problem by introducing the additional direction 1‖xnew‖2xnew contained in C. See more
discussion in Section 8.
2.3. Statistical Inference for Individualized Treatment Effect
Combining x̂ᵀnewβ1 and x̂
ᵀ
newβ2, we propose to estimate ∆new as
∆̂new = x̂
ᵀ
newβ1 − x̂ᵀnewβ2. (11)
Compared to the plug-in estimator xᵀnew(β̂1 − β̂2), the main advantage of ∆̂new is that
the variance of ∆̂new is typically dominating the bias of ∆̂new while the bias of the plug-in
estimator xᵀnew(β̂1−β̂2) is usually larger than its variance. (See Table 2 for the numerical
illustration.) Such a rebalance of bias and variance is extremely useful for uncertainty
quantification as the variance component is much easier to characterize than the bias
component.
To conduct HITS, it remains to quantify the variability of ∆̂new. The asymptotic
variance of ∆̂new is
V =
σ21
n1
ûᵀ1Σ̂1û1 +
σ22
n2
ûᵀ2Σ̂2û2, (12)
which can be estimated by
V̂ =
σ̂21
n1
ûᵀ1Σ̂1û1 +
σ̂22
n2
ûᵀ2Σ̂2û2. (13)
With ∆̂new and the variance estimator V̂, we may construct a CI for the ITE ∆new as
CI =
(
∆̂new − zα/2
√
V̂, ∆̂new + zα/2
√
V̂
)
(14)
and conduct HITS based on
φα = 1
(
∆̂new − zα
√
V̂ > 0
)
, (15)
where zα is the upper α quantile for the standard normal distribution. That is, if
∆̂new > zα
√
V̂, we would recommend subjects with xnew to receive treatment 1 over
treatment 2, vice versa.
It is worth noting that the proposed HITS procedure utilizes the xnew information in
the construction of the projection direction ûk, where both the constraints in (7) and (8)
depend on the observation xnew. For observations with different xnew, the corresponding
projection directions can be quite different. Second, the method is computationally
efficient as the bias correction step only requires the identification of two projection
directions instead of performing debiased of β̂k coordinate by coordinate.
Remark 1. To illustrate the main idea, we use the scaled LASSO method defined
in (3) to construct the initial estimators. However, the proposed method, specifically
the way of constructing the projection direction and also the following bias-correction,
works for a large class of initial estimators. This will be specified in Section 3.
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2.4. Application to Inference for Average Treatment Effect
In addition to the individualized treatment selection, the proposed method can also be
applied to study the average treatment effect (ATE). We follow the setting of Athey
et al. [2018] where k = 1 corresponds to the control group and k = 2 corresponds
to the treatment group. The average treatment over the treatment group is defined as
X¯ᵀ2(β2−β1) where X¯2 = 1n2
∑n2
i=1 X2,i. The statistical inference for the ATE X¯
ᵀ
2(β2−β1)
can be viewed as a special case of xᵀnew(β2−β1) with xnew = X¯2. Both the point estimator
(11) and interval estimator (14) can be directly applied here to construct point and
interval estimators for the ATE by taking xnew = X¯2.
These estimators are different from those proposed in Athey et al. [2018], where the
main distinction is the additional constraint (8) proposed in the current paper. Without
this additional condition, Athey et al. [2018] requires either of the following additional
conditions to guarantee the asymptotic limiting distribution, where the Bounded Loading
condition is imposed in Lemma 1 and the Overlap condition is stated as Assumption 5
in Athey et al. [2018]. We state both conditions in the following,
1 Bounded Loading. X¯2Σ
−1
1 X¯2 is assumed to be bounded;
2 Overlap. There exists a constant η > 0 such that η ≤ e(x) ≤ 1 − η for all x ∈ Rp
where e(x) is the probability of receiving the treatment for an individual with
covariates x.
Both conditions are actually limiting applications of the developed method to practical
settings. As X¯2Σ
−1
1 X¯2 is of the order
√
p/n, the bounded loading condition is not
realistic in the high-dimensional setting p  n. In addition, the overlap condition
does not hold if e(x) is the commonly used logit or probit probability function over an
unbounded support.
3. Theoretical Properties
We establish in this section the theoretical guarantees of the proposed CI and hypothesis
testing procedures. Before stating the theoretical properties, we first introduce some
general conditions for the initial estimators B̂1 and B̂2.
(B1) With probability at least 1− g(n1, n2) where g(n1, n2)→ 0, for k = 1, 2,
max
{
1√
nk
‖Xk(β̂k − βk)‖2, ‖β̂k − βk‖2
}
.
√
‖βk‖ log p
nk
, ‖β̂k − βk‖1 . ‖βk‖0
√
log p
nk
.
(B2) σ̂2k is a consistent estimator of σ
2
k for k = 1, 2, that is,
max
k=1,2
∣∣∣∣ σ̂2kσ2k − 1
∣∣∣∣ p→ 0.
Most of the estimators proposed in the high-dimension literature are shown to satisfy the
above conditions of estimating the regression vector and the variance of the regression
error under various conditions. See Sun and Zhang [2012], Belloni et al. [2011], Bickel
et al. [2009] and the reference within for more details. In addition, we assume the
following conditions on the design and the errors, {X1,i, 1,i}1≤i≤n1 and {X2,i, 2,i}1≤i≤n2 .
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(A1) For k = 1, 2, the rows Xk,i are i.i.d. p-dimensional sub-gaussian random vectors
with mean µk = EXk,i and the second order moment Σk = E(Xk,iXᵀk,i) where
1/M1 ≤ λmin (Σk) ≤ λmax (Σk) ≤M1 for M1 ≥ 1.
(A2) The error vector k = (k,1, ..., k,nk)
ᵀ is independent of Xk with zero mean and
constant variance σ2k.
(A3) The errors 1 and 2 follow Gaussian distributions.
The assumptions (A1) and (A2) are standard assumptions for the design and the re-
gression error in the high-dimension literature. The condition (A3) is strong but is only
imposed here to establish the distributional results. Although this condition can be ex-
tended to the Sub-gaussian error, we use the Gaussianality condition (A3) to simply the
algorithm and also the technical analysis.
Before stating the theorem, we present some intuitions for the estimation error of the
proposed estimator, which relies on the following error decompositions of x̂ᵀnewβk,
x̂ᵀnewβk − xᵀnewβk = ûᵀk
1
nk
nk∑
i=1
Xk,ik,i +
(
Σ̂kûk − xnew
)ᵀ
(β̂k − βk). (16)
This decomposition (16) reflects the bias and variance decomposition of the proposed
bias-correction estimator x̂ᵀnewβk, where the first error term û
ᵀ
k
1
nk
∑nk
i=1 Xk,ik,i is the
variance term while the second error term (Σ̂kûk − xnew)ᵀ(β̂k − βk) is the remaining
bias term. A similar bias and variance decomposition for the estimator ∆̂new defined in
(11) can be established by applying the error decomposition in (16) with k = 1, 2. The
following theorem establishes the rate of convergence for ∆̂new.
Theorem 1. Suppose that the conditions (A1), (A2) and (B1) hold and ‖βk‖0 ≤
cnk/log p for k = 1, 2, then with probability larger than 1− p−c − g(n1, n2)− 1t ,∣∣∣∆̂new −∆new∣∣∣ . ‖xnew‖2(‖β1‖0 log p
n1
+
‖β2‖0 log p
n2
)
+ t‖xnew‖2
(
1√
n1
+
1√
n2
)
. (17)
In the above theorem, part of the convergence rate, ‖xnew‖2
(‖β1‖0 log p
n1
+ ‖β2‖0 log pn2
)
, is
an upper bound for the remaining bias of the proposed bias-corrected estimator while
‖xnew‖2
(
1√
n1
+ 1√n2
)
is an upper bound for the corresponding variance term. The fol-
lowing theorem shows that under the additional normal error distribution condition (A3)
and the stronger sparsity condition, the proposed estimator has an asymptotic normal
distribution.
Theorem 2. Suppose that the conditions (A1), (A2), (A3) and (B1) hold and ‖βk‖0 ≤
c
√
nk/log p for k = 1, 2, then
1√
V
(
∆̂new −∆new
)
d→ N(0, 1) (18)
where V is defined in (12).
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A key component of establishing the limiting distribution for ∆̂new is to show that the
variance term in (12) dominates the upper bound for the bias term in (17). We present
this important component in the following Lemma, which characterizes the magnitude
of the variance level V in (12).
Lemma 1. Suppose that the condition (A1) holds, then with probability larger than
1− p−c,
c0‖xnew‖2
(
1√
n1
+
1√
n2
)
≤
√
V ≤ C0‖xnew‖2
(
1√
n1
+
1√
n2
)
, (19)
for some positive constants c0, C0 > 0.
We shall highlight that such a characterization of the variance level, mainly the lower
bound of (19), is only achieved through incorporating the novel additional constraint
(8) to identify the projection direction. Without this additional constraint, as shown in
Proposition 2, the variance level will be vanishing and hence the lower bound in (19)
does not hold.
In the following, we discuss two corollaries of Theorem 2, one for the hypothesis
testing problem (2) related to the individualized treatment selection and the other for
construction of CIs for the ITE ∆new. Regarding the hypothesis testing problem, we
consider the following parameter space
Θ (s) =
{
θ =
(
B1,Σ1
B2,Σ2
)
: ‖βk‖0 ≤ s, 0 < σk ≤M0, λmin(Σk) ≥ c0, for k = 1, 2
}
, (20)
for some positive constants M0 > 0 and c0 > 0. Then we define the null hypothesis
parameter space as
H0(s) =
{
θ =
(
B1,Σ1
B2,Σ2
)
∈ Θ (s) : xᵀnew (β1 − β2) ≤ 0
}
(21)
and the local alternative parameter space as
H1(s, δ0) =
{
θ =
(
B1,Σ1
B2,Σ2
)
∈ Θ (s) : xᵀnew (β1 − β2) = δ0‖xnew‖2
(
1√
n1
+
1√
n2
)}
, (22)
for δ0 > 0. The following Corollary provides the theoretical guarantee for the individ-
ualized treatment selection, where the type I error of the proposed HITS procedure in
(15) is controlled and the asymptotic power curve is also established.
Corollary 1. Suppose that the conditions (A1), (A2), (A3) and (B1), (B2) hold
and ‖βk‖0 ≤ c√nk/log p for k = 1, 2, then for any xnew ∈ Rp, the type I error of the
proposed test φα defined in (15) is controlled as,
lim
min{n1,n2}→∞
sup
θ∈H0
Pθ (φα = 1) ≤ α . (23)
For any given θ ∈ H1(δ0) and any xnew ∈ Rp, the asymptotic power of the test φα is
lim
min{n1,n2}→∞
Pθ (φα = 1) = 1− Φ−1
(
zα − δ0√
V
‖xnew‖2
(
1√
n1
+
1√
n2
))
. (24)
12 Cai, Cai & Guo
Together with Lemma 1, we observe that the proposed test is powerful as long as δ0 →∞,
where δ0 controls the local alternative defined in (22). The main massage for a real
application is that the individualized treatment selection would be easier if the collected
data set has larger sample sizes n1 and n2 and also the future observation of interest
has a smaller `2 norm. This phenomenon is especially interesting for the individualized
treatment selection with high-dimensional covariates, where the corresponding norm
‖xnew‖2 can be of different orders of magnitude. See Section 6 for the related numerical
illustration.
In addition to the hypothesis testing procedure, we also establish the coverage of the
proposed CI in (14) for ITE ∆new,
Corollary 2. Suppose that (A1), (A2), (A3) and (B1), (B2) hold and ‖βk‖0 ≤
c
√
nk/log p for k = 1, 2. Then the coverage property of the proposed CI defined in (14)
is
lim
min{n1,n2}→∞
Pθ (∆new ∈ CI) ≥ 1− α for any xnew ∈ Rp. (25)
Another important perspective of CI construction is the precision of the CIs, which
can be measured by the length. It follows from Lemma 1 that the length of the con-
structed CI in (14) is controlled at the order of magnitude ‖xnew‖2
(
1√
n1
+ 1√n2
)
, which
means that the length depends on both the sample sizes n1 and n2 and also the `2 norm
of the future observation ‖xnew‖2. For observations with different xnew, the lengths of the
corresponding CIs for ITE ∆new can be quite different, where the length is determined
by ‖xnew‖2 and the numerical illustration is present in Section 6.
4. Optimality for Hypothesis Testing
In this section, we investigate the optimality of the proposed procedure in the hypothesis
testing framework from two perspectives, minimaxity and adaptivity. We introduce the
optimality framework in Section 4.1, present the detailed results in Section 4.2, and
compare with the optimality of confidence intervals in Section 4.3.
4.1. Optimality Framework for Hypothesis Testing: Minimaxity and Adaptivity
The performance of a testing procedure can be evaluated in terms of its size (type I error
probability) and its power (or type II error probability). For a given test φ and a null
parameter space H0(s), its size is
α(s, φ) = sup
θ∈H0(s)
Eθφ. (26)
It has been shown in Corollary 1 that the proposed test φα satisfies α(s, φα) ≤ α. To
investigate the power, we consider the following local alternative parameter space
H1(s, τ) = {θ ∈ Θ(s) : xᵀnew (β1 − β2) = τ} , (27)
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for a given τ > 0. The power of a test φ over the parameter space H1(s, τ) is
ω(s, τ, φ) = inf
θ∈H1(s,τ)
Eθφ. (28)
With a larger value of τ , the alternative parameter space is further away from the null
parameter space and hence it is easier to construct a test of higher power. The minimax
optimality can be reduced to identifying the smallest τ such that the size is controlled
over H0(s) and the corresponding power over H1(s, τ) is large, that is,
τmini(s,xnew) = arg min
τ
{
τ : sup
φ:α(s,φ)≤α
ω(s, τ, φ) ≥ 1− η
}
, (29)
where η ∈ [0, 1) is a small positive constant controlling the type II error probability. The
quantity τmini(s,xnew) depends on xnew, the sparsity level s and the constants α, η ∈
(0, 1). Throughout the discussion, we omit α and η in the arguments of τmini(s,xnew) for
simplicity. This quantity τmini(s,xnew) is referred to as the minimax detection boundary
of the hypothesis testing problem (2). In other words, τmini(s,xnew) is the minimum
distance such that there exists a test controlling size and achieving a good power. If a
test φ satisfies the following property,
α(s, φ) ≤ α and ω(s, φ, τ) ≥ 1− η for τ  τmini(s,xnew) (30)
then φ is defined to be minimax optimal.
The minimax detection boundary in (29) is defined for a given sparsity level s, which
is assumed to be known a priori. However, the exact sparsity level is typically unknown
in practice. Hence, it is also of great importance to consider the optimality from the
following two perspectives on adaptivity,
Q1. Whether it is possible to construct a test achieving the minimax detection boundary
defined in (29) if the true sparsity level s is unknown
Q2. What is the optimal procedure in absence of accurate sparsity information?
To facilitate the definition of adaptivity, we consider the case of two sparsity levels,
s ≤ su. Here s denotes the true sparsity level, which is typically not available in practice
while su denotes the prior knowledge of an upper bound for the sparsity level. If we do
not have a good prior knowledge about the sparsity level s, then su can be much larger
than s. To answer the aforementioned questions on adaptivity, we assume that only
the upper bound su is known instead of the exact sparsity level s. As a consequence,
a testing procedure needs to be constructed with the size uniformly controlled over the
parameter space H0(su),
α(su, φ) = sup
θ∈H0(su)
Eθφ ≤ α. (31)
In contrast to (26), the control of size is with respect to H0(su), a larger parameter space
than H0(s), due to the fact that the true sparsity level is unknown. Similar to (29), we
define the adaptive detection boundary τadap(su, s,xnew) as
τadap(su, s,xnew) = arg min
τ
{
τ : sup
φ:α(su,φ)≤α
ω(s, τ, φ) ≥ 1− η
}
. (32)
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Comparing (32) with (29), the imprecise information about the sparsity level only affects
the control of size, where the power functions in (32) and (29) are evaluated over the
same parameter space, H1(s, τ). If a test φ satisfies the following property,
α(su, φ) ≤ α and ω(s, τ, φ) ≥ 1− η for τ  τadap(su, s,xnew) (33)
then φ is defined to be adaptive optimal. The question Q2 can be addressed using the
adaptive detection boundary τadap(su, s,xnew) and an adaptive optimal test would be
the best that we can aim for if there is lack of accurate information on sparsity.
The quantities τmini(s,xnew) and τadap(su, s,xnew) do not depend on the specific test-
ing procedure but mainly reflect the difficulty of the testing problem (2), which depends
on the parameter space and also the loading vector xnew. The question Q1 can be
addressed through comparing τmini(s,xnew) and τadap(su, s,xnew); if τmini(s,xnew) 
τadap(su, s,xnew), then the hypothesis testing problem (2) is defined to be adaptive,
that is, even if one does not know the exact sparsity level in the construction of the
test, it is possible to construct a test as if the sparsity level is known; in contrast, if
τmini(s,xnew)  τadap(su, s,xnew), the hypothesis testing problem (2) is defined to be
not adaptive. The information on the sparsity level is crucial. In this case, the adaptive
detection boundary itself is of great interest as it quantifies the effect of the knowledge
of sparsity level.
As a concluding remark, the minimax detection boundary characterizes the difficulty
of the testing problem for the case of known sparsity level while the adaptive detection
boundary characterizes a more challenging problem due to the unknown sparsity level.
The construction of an adaptive optimal test satisfying (33) is more useful in practice
than that of a minimax optimal test because the exact sparsity level is typically unknown
in applications.
4.2. Detection Boundary for Testing Problem (2)
We now demonstrate the optimality of the proposed procedure by considering the follow-
ing two types of loadings xnew, Exact Loading, indexed with (E), and Decaying Loading,
indexed with (D).
(E) Exact Loading. xnew is defined as an exact loading if it satisfies,
c0 ≤ max{i:xnew,i 6=0} |xnew,i| / min{i:xnew,i 6=0} |xnew,i| ≤ C0, (34)
for some positive constants C0 ≥ c0 > 0. The condition (34) assumes that all non-zero
coefficients of the loading vector xnew are of the same order of magnitude and hence the
complexity of an exact loading xnew is captured by its sparsity level. We calibrate the
sparsity levels of the regression vectors as
s = pγ , su = p
γu for 0 ≤ γ < γu ≤ 1, (35)
and calibrate the sparsity of the exact loading xnew as
‖xnew‖0 = pγnew for 0 ≤ γnew ≤ 1. (36)
Based on the sparsity level of xnew, we define the following types of loadings,
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(E1) xnew is called an exact sparse loading if it satisfies (34) with γnew ≤ 2γ;
(E2) xnew is called an exact dense loading if it satisfies (34) with γnew > 2γ;
Exact loadings are commonly seen in the genetic studies, where the loading xnew
represents a specific observation’s SNP and only takes the value from {0, 1, 2}.
(D) Decaying Loading. Let
∣∣xnew,(1)∣∣ ≥ ∣∣xnew,(2)∣∣ ≥ · · · ≥ ∣∣xnew,(p)∣∣ be the sorted
coordinates of |xnew|. We say that xnew is decaying at the rate δ if∣∣xnew,(i)∣∣  i−δ for some constant δ ≥ 0. (37)
Depending on the decaying rate δ, we define the following two types of loadings,
(D1) xnew is called a fast decaying loading if it satisfies (37) with δ ≥ 12 ;
(D2) xnew is called a slow decaying loading if it satisfies (37) with 0 ≤ δ < 12 .
To simplify the presentation, we present the optimality results for the case n1  n2,
denoted by n and the results can be extended to the case where n1 and n2 are of different
orders. In the following, we focus on the exact loading and give a summary of the results
for the decaying loading in Table 1. The detailed results about decaying loadings will
be deferred to Section A in the supplement. The following theorem establishes the lower
bounds for the adaptive detection boundary for exact loadings.
Theorem 3. Suppose that s ≤ su . nlog p . We calibrate s, su and ‖xnew‖0 by γ, γu
and γnew, respectively, as defined in (35) and (36).
(E1) If xnew is an exact sparse loading, then
τadap(su, s,xnew) &
√‖xnew‖0‖xnew‖∞√
n
 ‖xnew‖2√
n
; (38)
(E2) If xnew is an exact dense loading, then
τadap(su, s,xnew) &
‖xnew‖∞su
√
log p
n if γnew > 2γu;
‖xnew‖2√
n
if γnew ≤ 2γu.
(39)
We shall point out here that establishing the adaptive detection boundaries in Theo-
rem 3 requires technical novelty. A closely related problem, adaptivity of confidence sets,
has been carefully studied in the context of high-dimensional linear regression [Nickl and
van de Geer, 2013, Cai and Guo, 2017, 2018a]. However, it requires new technical tools
to establish the adaptive detection boundaries, due to the different geometries demon-
strated in Figure 1. The main idea of constructing the lower bounds in Nickl and van de
Geer [2013], Cai and Guo [2017, 2018a] is illustrated in Figure 2(a), where one interior
point is first chosen in the smaller parameter space Θ(s) and the corresponding least
favorable set is constructed in the larger parameter space Θ(su) such that they are not
distinguishable.
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In comparison to Figure 2(a), the lower bound construction for the testing problem
related to Figure 2(b) is more challenging due to the fact that the alternative parameter
space H1(su, τ) does not contain the indifference region 0 < xᵀnew(β1 − β2) < τ . A new
technique, transferring technique, is developed for establishing the sharp lower bounds
for the adaptive detection boundary. Define the index of xnew with the largest absolute
value as imax = arg max |xnew,i|. In constructing the least favorable set in H0(su), we first
perturb the regression coefficients at other locations except for imax and then choose the
regression coefficient at imax such that xnew,imax(β1,imax−β2,imax) > 0 and xᵀnew(β1−β2) ≤
0; in construction of the corresponding least favorable set in H1(s, τ), we simply set the
regression coefficient with index imax to be the same as the corresponding coefficient
at imax in H0(su) and set all other coefficients to be zero. The above construction
is transferring the parameter space complexity from H0(su) to H1(s, τ) by matching
the regression coefficient at imax. Such a transferring technique can be of independent
interest in establishing the adaptive detection boundaries for other inference problems.
Θ0(s)
Θ1(su)
(a)
H0(su) H1(s, τ)
xᵀnew(β1 − β2) = 0
xᵀnew(β1 − β2) = τ
(b)
Fig. 1: (a) Null and alternative parameter spaces for the confidence set construction;
(b) Null and alternative parameter spaces for the hypothesis testing problem.
The following corollary presents the matched upper bounds for the detection bound-
aries established in Theorem 3 over certain regimes.
Corollary 3. Suppose that s ≤ su .
√
n
log p .
(E1) If the loading xnew is an exact sparse loading, then
τadap(su, s,xnew)  τmini(s,xnew)  ‖xnew‖2√
n
(40)
(E2) If the loading xnew is an exact dense loading, then the results are divided into the
following two cases,
(E2-a) If γ < γu <
1
2γnew, then
τadap(su, s,xnew)  ‖xnew‖∞su
√
log p
n
 τmini(s,xnew)  ‖xnew‖∞s
√
log p
n
.
(41)
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(E2-b) If γ < 12γnew ≤ γu, then
τadap(su, s,xnew)  ‖xnew‖2√
n
 τmini(s,xnew)  ‖xnew‖∞s
√
log p
n
. (42)
The question Q1 about the possibility of adaptivity of the testing problem (2) can be
addressed by the above corollary, where the testing problem is adaptive for the exact
sparse loading case (E1) but not adaptive for the exact dense loading case (E2). The
specific cut-off for the “dense” and “sparse” cases occurs at γnew = 2γ. For the case (E2),
depending on the value of γu, the adaptive detection boundaries can be quite different.
The case (E2-a) corresponds to the case that the exact sparsity level is unknown but the
upper bound su is relatively precise (both γ and γu are below 1/2 · γnew), then we can
utilize the proposed procedure φα with the sparsity information su to construct a testing
procedure matching the adaptive detection boundary. See the detailed construction in
Section B of the supplement. In contrast, the case (E2-b) corresponds to the setting
where the prior knowledge of the upper bound su is quite rough. For such a case, the
proposed testing procedure φα defined in (15) achieves the adaptive detection boundary
τadap(su, s,xnew), but not the minimax detection boundary τmini(s,xnew).
Beyond answering Q1, we can also address the question Q2 with the following corol-
lary, which considers the practical setting that there is limited information on sparsity
and presents a unified optimality result for the case of exact loadings.
Corollary 4. Suppose that s ≤ su .
√
n
log p and γu ≥ 12γnew. Then the testing
procedure φα in (15) achieves the adaptive detection boundary τadap(su, s,xnew)  ‖xnew‖2√n
for any xnew satisfying (34).
The above Corollary states that, in absence of accurate sparsity information, the pro-
posed procedure φα is an adaptive optimal test for all exact loadings xnew.
4.3. Comparison with Existing Optimality Results on CI
It is helpful to compare the established optimality results to the related work Cai and Guo
[2017] on the minimaxity and adaptivity of confidence intervals for the linear contrast in
the one-sample high-dimensional regression. Beyond the technical difference highlighted
in Figure 1, we also observed the following three distinct features between the present
paper and Cai and Guo [2017].
1 The current paper closes the gap between the definitions of exact sparse and dense
loading in Cai and Guo [2017], where the lower bounds for exact sparse loading
only covered the case γnew ≤ γ instead of the complete regime γnew ≤ 2γ defined
in the current paper.
2 The result in the current paper considers the additional setting (E2-b) than those
in Cai and Guo [2017], which corresponds to the case where the knowledge on
the sparsity level is rough. This additional result is not only of technical interest,
but is of broad implications to practical applications. It addresses the important
question, “what is the optimal testing procedure in a practical setting where no
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accurate sparsity information is available? ” As shown in Corollary 4, the proposed
procedure φα is an adaptive optimal test for all exact loadings xnew.
3 In addition, the technical tools for general loading xnew have been developed in
Theorem 4, which can handle the loadings not considered in Cai and Guo [2017].
Specifically, we summarize in Table 1 the optimality results for the decaying loading
defined in (37). As shown in Table 1, the fast decaying loading (D1) is similar to
the exact sparse loading (E1) while the slow decaying loading (D2) is similar to
the exact dense loading (E2). In contrast, the decaying loading has the distinct
setting (D2-c) from the exact loading case where the hypothesis testing problem (2)
is adaptive if both γ and γu are above 1/2. See the detailed discussion in Section
A of the supplement.
δ Setting γ, γu τmini(s,xnew) Rel τadap(su, s,xnew) Adpt
[1/2,∞) (D1) γ < γu ‖xnew‖2√n 
‖xnew‖2√
n
Yes
[0, 1/2)
(D2-a) γ < γu ≤ 12 s
1−2δ√
n
(log p)
1
2
−δ  s1−2δu√
n
(log p)
1
2
−δ No
(D2-b) γ < 12 ≤ γu s
1−2δ√
n
(log p)
1
2
−δ  ‖xnew‖2√
n
No
(D2-c) 12 ≤ γ < γu ‖xnew‖2√n 
‖xnew‖2√
n
Yes
Table 1: Optimality for the decaying loading xnew defined in (37) over the regime s .
su .
√
n
log p . The column indexed with “Rel” compares τmini(s,xnew) and τadap(su, s,xnew)
and the column indexed with “Adpt” reports whether the testing problem is adaptive
or not for the corresponding setting.
5. Uncertainty Quantification related to High-dimensional Prediction
As mentioned in the introduction, the hypothesis testing method developed in the current
paper can also be used for the prediction problem in a single high-dimensional regression.
Consider the regression model with i.i.d observations {(Xi·, yi)}1≤i≤n satisfying
yi = X
ᵀ
i·β + i where i
iid∼ N(0, σ2) for 1 ≤ i ≤ n, (43)
and {i}1≤i≤n is independent of the design matrix X. The problem of interest is inference
for the conditional expectation E(yi | Xi· = xnew) = xᵀnewβ. Uncertainty quantification for
xᵀ
new
β is a simpler version of the testing problem (15). Due to its importance and for
clarity, we present a separate result on this prediction problem. We use β̂ to denote the
scaled Lasso estimator of β based on the observations {(Xi·, yi)}1≤i≤n and construct the
following bias-corrected point estimator,
x̂
nᵀew
β = xᵀ
new
β̂ + ûᵀ
1
n
n∑
i=1
Xi·
(
yi −Xᵀi·β̂
)
(44)
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with the projection direction defined as
û = arg min
u∈Rp
uᵀΣ̂u subject to
∥∥∥Σ̂u− xnew∥∥∥∞ ≤ ‖xnew‖2λ∣∣∣xᵀnewΣ̂u− ‖xnew‖22∣∣∣ ≤ ‖xnew‖22λ,
where Σ̂ = 1n
∑n
i=1Xi·X
ᵀ
i· and λ 
√
log p/n. The key difference between this construc-
tion and the projection construction for the single regression coefficient in Zhang and
Zhang [2014], van de Geer et al. [2014], Javanmard and Montanari [2014], Athey et al.
[2018] is the additional constraint
∣∣∣xᵀnewΣ̂u− ‖xnew‖22∣∣∣ ≤ ‖xnew‖22λ, which guarantees
the asymptotic limiting distribution for any xnew ∈ Rp. We introduce the following
general condition for the initial estimator β̂ and then establish the limiting distribution
for the point estimator x̂
nᵀew
β in Corollary 5.
(P) With probability at least 1− g(n) where g(n)→ 0,
max
{
1√
n
‖X(β̂ − β)‖2, ‖β̂ − β‖2
}
.
√
‖β‖ log p
n
, ‖β̂ − β‖1 . ‖β‖0
√
log p
n
.
Corollary 5. Suppose that the regression model (43) holds where ‖β‖0 ≤ c
√
n/log p
and the rows Xi· are i.i.d. p-dimensional sub-gaussian random vectors with mean µ =
EXi· and the second order moment Σ = E(Xi·Xᵀi·) satisfying c0 ≤ λmin (Σ) ≤ λmax (Σ) ≤
C0 for positive constants C0, c0 > 0. For any initial estimator β̂ satisfying the condition
(P), then
1√
σ2ûᵀΣ̂û/n
(
x̂
nᵀew
β − xᵀ
new
β
)
d→ N(0, 1). (45)
Based on this corollary, we use V̂ = σ̂2ûᵀΣ̂û/n to quantify the uncertainty of the
estimator x̂
nᵀew
β, which leads to the following CI for xᵀ
new
β,
CIPred =
(
x̂
nᵀew
β − zα/2
√
σ̂2
n
ûᵀΣ̂û, x̂
nᵀew
β + zα/2
√
σ̂2
n
ûᵀΣ̂û
)
.
If σ̂2 is a consistent estimator of σ2, then this constructed CI will be guaranteed to have
coverage for xᵀnewβ for any xnew ∈ Rp. The optimality theory established in Section 4
can be easily extended to the one-sample case.
6. Simulation Studies
This section investigates the numerical performance of HITS and the CI construction
through simulation studies and shows that the HITS method outperforms the existing
methods in the literature.
Before presenting the numerical results, we first introduce the equivalent dual form
to find the projection direction defined in (7) and (8).
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Proposition 1. The constrained optimizer ûk ∈ Rp for k = 1, 2 defined in (7) and
(8) can be computed in the form of
ûk = v̂
k
−1 +
xnew
‖xnew‖2 v̂
k
1 . (46)
where v̂k ∈ Rp+1 is defined as
v̂k = arg min
v∈Rp+1
{
1
4
vᵀHᵀΣ̂kHv + xᵀnewHv + λk‖xnew‖2 · ‖v‖1
}
(47)
with H =
[
xnew
‖xnew‖2 , Ip×p
]
∈ Rp×(p+1).
By the above proposition, we transform the constrained minimization problem to the un-
constrained minimization problem in (47), which can be solved using standard penalized
least squares algorithms.
We next present simulation results from two settings with different structures for
xnew. We discuss the setting with xnew generated from Gaussian distributions in Section
6.1 and the setting with decaying loadings in Section 6.2. Throughout, we consider
p = 501 including intercept and equal sample sizes for the two treatment groups with
n1 = n2 = n and various choices of n. For simplicity, we generate the covariates
(Xk,i)−1 from the same multivariate normal distribution with zero mean and covariance
Σ = [0.51+|j−l|](p−1)×(p−1). To generate Y1 and Y2, we generate k,i from the standard
normal and set β1,1 = −0.1, β1,j = −1(2 ≤ j ≤ 11)0.4(j − 1), β2,1 = −0.5, and β2,j =
0.2(j − 1)1(2 ≤ j ≤ 6).
6.1. General Loading
We first consider the case with the loading xnew being a dense vector, generated via two
steps. In the first step, we generate xbasis = [1,x
ᵀ
basis,−1]
ᵀ ∈ Rp with xbasis,−1 ∼ N(0,Σ).
In the second step, we generate xnew based on xbasis in two specific ways,
(a) In Setting 1, we generate xnew as a shrunk version of xbasis with
xnew,j = S · 1(j ≥ 12) · xbasis,j , for j = 1, ..., p (48)
and S ∈ {1, 0.5, 0.2, 0.1, 0.05}.
(b) For Setting 2, we let
xnew,j = 1(j = 1)− 2
3
1(j = 2) + S · 1(j ≥ 12) · xbasis,j for j = 1, ..., p (49)
and S ∈ {1, 0.5, 0.2, 0.1, 0.05}.
Under the above configurations, the scale parameter S controls the magnitude of the
noise variables in xnew. As S increases, ‖xnew‖2 increases but ∆new remains the same for
all choices of S. Setting 1 corresponds to an alternative setting with ∆new = 1.082 and
setting 2 corresponds to the null setting with ∆new = 0.
Individualized Treatment Selection 21
We report the simulation results based on 1000 replications for each setting in Tables
2 and 3. Under setting 1, as the sample size n increases and as the magnitude of the
noise variables decreases, the statistical inference problem becomes “easier” in the sense
that the CI length and root mean square error (RM) get smaller, the empirical rejection
rate (ERR) (i.e. power) gets closer to 100%. This is consistent with the established
theoretical results. The most challenging setting for HITS is the case with S = 1, where
the noise variables are of high magnitude. As a result, the HITS procedure has a lower
power in detecting the treatment effect even when n = 1000. When S drops to 0.2, the
power of the HITS is about 72% when n = 200 and 95% when n = 400. Across all
sample sizes considered including when n = 100, the empirical coverage of the CIs are
close to the nominal level.
Besides reporting the performance of the proposed estimator, we also compare the
HITS method to two other estimators, 1) the plug-in Lasso estimator; and 2) the plug-in
debiased estimator. For the plug-in Lasso estimator, we estimating the regression vectors
by the scaled Lasso estimator implemented in the R package FLARE [Li et al., 2015].
For the plug-in debiased estimators, we introduce an alternative debiased estimator,
∆˜new = x
ᵀ
new
(β˜1 − β˜2), where β˜k,j is obtained based on the debiased plug-in estimator
proposed in Javanmard and Montanari [2014] using the code posted in https://web.
stanford.edu/~montanar/sslasso/code.html.
In Table 2, we first compare the proposed estimator (HITS) to these two plug-in
estimators (plug-in Lasso estimator is shorthanded as “Lasso” and plug-in debiased esti-
mator is shorthanded as “Deb”) in terms of RM (Root Mean Squared Error). Across all
settings, in comparison to the plug-in debiased estimator, the proposed HITS estimator
always have a smaller RM; in comparison to the plug-in Lasso estimator, the proposed
estimator attained substantially smaller bias but at the expense of larger variability,
reflecting the bias-variance trade-off. Specifically, when S is small (taking values in
{0.2, 0, 1, 0.05}), the proposed estimator generally has a smaller RM than the plug-in
Lasso estimator. When S = 1, 0.5 in which case xnew is very dense, the proposed HITS
estimator has a much larger variability compared to plug-in Lasso estimator. This sug-
gests that under the very challenging dense scenario, a high price is paid to ensure the
validity of the interval estimation.
We further compare the proposed estimator with these two plug-in estimators in
terms of hypothesis testing. We first comment that the plug-in Lasso estimator is not
useful in hypothesis testing or CI construction due to the fact that the bias component
is as large as the variance. In contrast, the variance component of both the proposed
HITS estimator and also the plug-in debiased estimator dominates the corresponding
bias component. Due to this reason, we only report the empirical comparison between
the HITS method and the plug-in debiased method. As illustrated in the coverage
property, the empirical coverage of CIs based on the plug-in debiased is about 10%
below the nominal level while our proposed CI achieves the nominal level.
In Table 3, we report results under setting 2 where the null hypothesis holds. We
observe a similar pattern as in setting 1 for estimation precision and relative performance
compared to the plug-in Lasso and debiased estimators. All the ERRs in this case, which
correspond to the empirical size, are close to the nominal level 5% for the proposed HITS
method while the corresponding ERRs cannot be controlled for the plug-in debiased
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estimators.
6.2. Decaying Loading
In this session, we generate the decaying loading xnew as xnew,j = 0.5 · j−δ where
δ ∈ {0, 0.1, 0.25, 0.5}, and defer more detailed simulation results to Section D in the
supplement. We report the performance of the proposed HITS method for the decay-
ing loading in Table 4. Specifically, with an increasing sample size, the empirical power
reaches 100%, the empirical coverage rate reaches 95% and the length of CIs gets shorter.
A similar bias-and-variance tradeoff is observed, where across all settings, in comparison
to the plug-in Lasso estimator, both the proposed HITS estimator and the plug-in debi-
ased estimator attained substantially smaller bias but at the expense of larger variability.
For the slow or no decay settings with δ = 0 or 0.1, the proposed HITS estimator has
uniformly higher power and shorter length of CIs than the debiased plug-in estimator
∆˜new while the coverage of the CIs constructed based on both estimators are close to
95%. In the relatively faster decay setting with δ = 0.5, ∆˜new and our proposed ∆̂new
perform more similarly. This is not surprising since the case of fast decaying loading is
similar to the sparse loading case and the plugging-in of the debiased estimators can be
shown to work if the loading is sufficiently sparse (or decaying sufficiently fast). However,
we shall emphasize that ∆˜new is substantially more computationally intensive than ∆̂new.
The calculation of ∆̂new requires four fittings of Lasso-type algorithms twice whereas ∆˜new
requires 2p+ 2 fittings.
7. Real Data Analysis
Tumor Necrosis Factor (TNF) is an inflammatory cytokine important for immunity
and inflammation. TNF blockade therapy has found its success in treating RA [Taylor
and Feldmann, 2009]. However, the effect of anti-TNF varies greatly among patients
and multiple genetic markers have been identified as potentially predictive of anti-TNF
response [Padyukov et al., 2003, Liu et al., 2008, Chatzikyriakidou et al., 2007]. We
seek to estimate ITE of anti-TNF in reducing inflammation for treating RA using EHR
data from PHS as described in Section 1. Here, the inflammation is measured by the
inflammation marker, C-reactive Protein (CRP). Since a higher value of CRP is more
indicative of a worse treatment response, we define Y = − log CRP.
The analyses include n = 183 RA patients who are free of coronary artery disease,
out of which n1 = 92 were on the combination therapy and n2 = 91 on methotraxate
alone. To sufficiently control for potential confounders, we extracted a wide range of pre-
dictors from the EHR including past medical history and various indications of disease
duration and severity on RA. We included both potential confounders and predictors of
CRP in X. This results in a total of p = 171 candidate predictors, including diagnostic
codes of RA and comorbidities such as systemic lupus erythematosus (SLE) and dia-
betes, past history of lab results including C-reactive protein (CRP), rheumatoid factor
(RF), and anticyclic citrullinated peptide (CCP), prescriptions of other RA medications
including Gold and Plaquenil, as well as counts of NLP mentions for a range of clinical
terms including disease conditions and medications. Since counts of diagnosis or med-
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ERR Coverage Len HITS Lasso Deb
S n HITS Deb HITS Deb HITS RM Bias SE RM Bias SE RM Bias SE
1
100 0.10 0.25 0.97 0.81 9.33 2.10 0.05 2.10 0.90 0.61 0.66 2.56 0.07 2.56
200 0.11 0.26 0.97 0.86 7.65 1.79 0.01 1.79 0.61 0.41 0.45 1.97 0.02 1.97
400 0.20 0.30 0.97 0.85 5.38 1.30 0.03 1.30 0.43 0.31 0.30 1.62 0.02 1.62
600 0.23 0.36 0.97 0.87 4.47 1.02 0.07 1.02 0.34 0.24 0.24 1.34 0.05 1.34
1000 0.34 0.32 0.97 0.85 3.49 0.83 0.02 0.83 0.26 0.19 0.19 1.49 0.05 1.49
0.5
100 0.16 0.36 0.96 0.83 4.80 1.10 0.13 1.09 0.81 0.64 0.49 1.27 0.03 1.27
200 0.30 0.46 0.95 0.83 3.90 0.96 0.08 0.96 0.51 0.40 0.33 1.09 0.08 1.09
400 0.49 0.57 0.94 0.86 2.74 0.67 0.09 0.67 0.34 0.25 0.22 0.82 0.05 0.81
600 0.59 0.62 0.96 0.84 2.30 0.57 0.02 0.57 0.29 0.23 0.17 0.73 0.02 0.73
1000 0.76 0.52 0.96 0.87 1.80 0.45 0.02 0.45 0.23 0.18 0.14 0.76 0.12 0.75
0.2
100 0.59 0.77 0.94 0.80 2.27 0.60 0.04 0.60 0.72 0.58 0.42 0.65 0.07 0.65
200 0.72 0.82 0.95 0.83 1.81 0.45 0.03 0.45 0.50 0.41 0.28 0.51 0.00 0.51
400 0.95 0.95 0.95 0.85 1.28 0.32 0.05 0.32 0.32 0.26 0.20 0.39 0.04 0.38
600 0.98 0.98 0.94 0.84 1.10 0.28 0.02 0.28 0.27 0.22 0.16 0.32 0.00 0.32
1000 1.00 0.98 0.95 0.88 0.85 0.21 0.02 0.21 0.21 0.17 0.12 0.33 0.01 0.33
0.1
100 0.75 0.91 0.91 0.80 1.67 0.48 0.06 0.48 0.70 0.56 0.42 0.51 0.07 0.50
200 0.94 0.97 0.93 0.80 1.29 0.35 0.01 0.35 0.49 0.40 0.29 0.38 0.05 0.38
400 1.00 1.00 0.94 0.83 0.91 0.24 0.01 0.24 0.33 0.28 0.19 0.28 0.02 0.28
600 1.00 1.00 0.96 0.87 0.80 0.19 0.02 0.19 0.28 0.24 0.16 0.22 0.02 0.22
1000 1.00 1.00 0.94 0.84 0.62 0.16 0.02 0.16 0.20 0.16 0.12 0.24 0.01 0.24
0.05
100 0.78 0.92 0.85 0.72 1.47 0.49 0.07 0.48 0.72 0.58 0.44 0.48 0.07 0.47
200 0.98 1.00 0.93 0.82 1.13 0.31 0.03 0.31 0.47 0.38 0.28 0.33 0.08 0.32
400 1.00 1.00 0.95 0.86 0.80 0.21 0.02 0.21 0.33 0.27 0.19 0.23 0.03 0.23
600 1.00 1.00 0.93 0.86 0.71 0.19 0.00 0.19 0.27 0.22 0.16 0.20 0.01 0.20
1000 1.00 1.00 0.94 0.87 0.55 0.14 0.02 0.14 0.19 0.15 0.12 0.20 0.02 0.20
Table 2: Performance of the HITS hypothesis testing, in comparison with the plug-in
Debiased Estimator (“Deb”), with respect to empirical rejection rate (ERR) as well as
the empirical coverage (Coverage) and length (Len) of the CIs under dense setting 1
where ∆new = 1.08. Reported also are the RM (Root Mean Squared Error), bias and the
standard error (SE) of the HITS estimator compared to the plug-in LASSO estimator
(“Lasso”) and the plug-in Debiased Estimator (“Deb”).
ication codes, referred to as codified (COD) mentions, are highly correlated with the
corresponding NLP mentions in the narrative notes, we combine the counts of COD and
NLP mentions of the same clinical concept to represent its frequency. The predictors
also include a number of single-nucleotide polymorphism (SNP) markers and genetic
risk scores identified as associated with RA risk or progression. All count variables were
transformed via x 7→ log(1 + x) and lab results were transformed by x 7→ log(x) since
their distributions are highly skewed. Missing indicator variables were created for past
history of lab measurements since the availability of lab results is indicative of disease
severity. We assume that conditional on X, the counterfactual outcomes are independent
of the treatment assignment A.
We applied our proposed procedures to estimate the ITE for individual patients.
Out of the p = 171 predictors, 8 of which were assigned with non-zero coefficients in
either treatment groups. The leading predictors, as measured by the magnitude of
{β̂1,j − β̂2,j , j = 1, ..., p}, include counts of SLE COD or NLP mentions, indicator of
no past history of CRP measurements, and SNPs including rs12506688, rs8043085 and
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ERR Coverage Len HITS Lasso Deb
S n HITS Deb HITS Deb HITS RM Bias SE RM Bias SE RM Bias SE
1
100 0.02 0.10 0.98 0.83 9.18 1.97 0.20 1.96 0.56 0.16 0.53 2.37 0.21 2.36
200 0.03 0.10 0.97 0.84 7.61 1.75 0.07 1.75 0.38 0.15 0.35 1.98 0.10 1.97
400 0.03 0.09 0.96 0.87 5.35 1.31 0.10 1.31 0.26 0.10 0.24 1.58 0.08 1.58
600 0.03 0.11 0.97 0.87 4.45 1.03 0.04 1.03 0.21 0.07 0.20 1.32 0.02 1.32
1000 0.03 0.10 0.97 0.83 3.49 0.82 0.05 0.81 0.16 0.06 0.15 1.53 0.08 1.53
0.5
100 0.02 0.13 0.97 0.82 4.68 1.00 0.04 1.00 0.38 0.21 0.31 1.24 0.02 1.24
200 0.04 0.13 0.97 0.84 3.82 0.91 0.04 0.91 0.26 0.15 0.21 1.02 0.02 1.02
400 0.03 0.07 0.96 0.87 2.70 0.62 0.07 0.62 0.17 0.09 0.14 0.76 0.08 0.75
600 0.03 0.09 0.97 0.86 2.24 0.52 0.02 0.52 0.15 0.09 0.12 0.68 0.04 0.68
1000 0.04 0.13 0.95 0.83 1.75 0.45 0.00 0.45 0.11 0.06 0.09 0.78 0.02 0.78
0.2
100 0.06 0.18 0.97 0.80 1.96 0.46 0.11 0.44 0.33 0.22 0.24 0.53 0.09 0.52
200 0.05 0.13 0.96 0.85 1.62 0.38 0.02 0.38 0.23 0.17 0.16 0.44 0.03 0.44
400 0.03 0.12 0.96 0.85 1.13 0.27 0.00 0.27 0.16 0.11 0.11 0.34 0.01 0.34
600 0.03 0.08 0.96 0.88 0.94 0.22 0.01 0.22 0.13 0.09 0.09 0.27 0.01 0.27
1000 0.03 0.09 0.97 0.88 0.74 0.18 0.01 0.18 0.10 0.07 0.07 0.31 0.01 0.31
0.1
100 0.07 0.20 0.93 0.77 1.12 0.29 0.05 0.29 0.31 0.21 0.22 0.33 0.04 0.32
200 0.04 0.12 0.96 0.84 0.94 0.23 0.01 0.23 0.21 0.15 0.15 0.25 0.01 0.25
400 0.04 0.11 0.96 0.87 0.66 0.16 0.00 0.16 0.16 0.12 0.10 0.19 0.01 0.19
600 0.03 0.10 0.95 0.87 0.55 0.13 0.01 0.13 0.13 0.09 0.09 0.16 0.00 0.16
1000 0.03 0.08 0.96 0.87 0.43 0.10 0.00 0.10 0.10 0.07 0.06 0.17 0.00 0.17
0.05
100 0.15 0.25 0.88 0.70 0.81 0.26 0.06 0.25 0.31 0.22 0.22 0.27 0.06 0.26
200 0.10 0.16 0.91 0.78 0.68 0.20 0.01 0.20 0.22 0.15 0.16 0.20 0.01 0.20
400 0.07 0.10 0.95 0.88 0.48 0.12 0.01 0.12 0.16 0.12 0.10 0.13 0.01 0.13
600 0.05 0.11 0.95 0.88 0.40 0.10 0.00 0.10 0.13 0.09 0.08 0.12 0.00 0.12
1000 0.06 0.11 0.95 0.91 0.31 0.08 0.00 0.08 0.10 0.07 0.07 0.12 0.01 0.12
Table 3: Performance of the HITS hypothesis testing, in comparison with the plug-in
Debiased Estimator (“Deb”), with respect to empirical rejection rate (ERR) as well as
the empirical coverage (Coverage) and length (Len) of the CIs under dense setting 2
where ∆new = 0. Reported also are the RM (Root Mean Squared Error), bias and the
standard error (SE) of the HITS estimator compared to the plug-in LASSO estimator
(“Lasso”) and the plug-in Debiased Estimator (“Deb”).
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ERR Coverage Len HITS Lasso Deb
δ n HITS Deb HITS Deb HITS Deb RM Bias SE RM Bias SE RM Bias SE
0
200 0.98 0.93 0.97 0.97 3.00 3.45 0.69 0.05 0.69 0.35 0.28 0.21 0.83 0.05 0.83
300 1.00 1.00 0.97 0.97 2.17 2.74 0.51 0.09 0.50 0.29 0.23 0.17 0.63 0.03 0.63
400 1.00 1.00 0.95 0.94 1.94 2.33 0.50 0.05 0.50 0.25 0.20 0.15 0.61 0.00 0.61
0.1
200 1.00 1.00 0.97 0.97 1.87 2.09 0.44 0.05 0.44 0.30 0.26 0.17 0.50 0.02 0.50
300 1.00 1.00 0.96 0.97 1.32 1.66 0.32 0.07 0.32 0.26 0.22 0.14 0.40 0.00 0.40
400 1.00 1.00 0.96 0.94 1.20 1.42 0.30 0.05 0.29 0.22 0.19 0.12 0.35 0.00 0.35
0.25
200 1.00 1.00 0.96 0.96 1.01 1.07 0.25 0.05 0.25 0.27 0.24 0.13 0.27 0.02 0.27
300 1.00 1.00 0.91 0.94 0.69 0.86 0.19 0.05 0.19 0.22 0.19 0.12 0.22 0.01 0.22
400 1.00 1.00 0.93 0.95 0.64 0.74 0.17 0.03 0.17 0.19 0.16 0.10 0.19 0.00 0.19
0.5
200 1.00 1.00 0.92 0.94 0.53 0.54 0.15 0.04 0.14 0.24 0.21 0.13 0.14 0.00 0.14
300 1.00 1.00 0.94 0.94 0.42 0.45 0.11 0.02 0.11 0.18 0.15 0.10 0.12 0.01 0.12
400 1.00 1.00 0.92 0.93 0.36 0.40 0.10 0.02 0.10 0.17 0.14 0.09 0.11 0.00 0.11
Table 4: Performance of the HITS hypothesis testing, in comparison with the plug-in
Debiased Estimator (“Deb”), with respect to empirical rejection rate (ERR) as well as
the empirical coverage (Coverage) and length (Len) of the CIs under the decaying loading
xnew,j = 0.5 ∗ j−δ. Reported also are the RM (Root Mean Squared Error), bias and the
standard error (SE) of the HITS estimator compared to the plug-in LASSO estimator
(“Lasso”) and the plug-in Debiased Estimator (“Deb”).
rs2843401. These predictors are generally consistent with results previously reported
in clinical studies. The anti-TNF has been shown as effective among patients with
presentations of both RA and SLE [Danion et al., 2017]. The rs8043085 SNP located in
the RASGRP1 gene is associated with an increased risk of sero-positive RA [Eyre et al.,
2012] and the combination therapy has been previously reported as being more beneficial
for sero-postive RA than for sero-negative RA [Seegobin et al., 2014]. The rs2843401 SNP
in the MMLE1 gene has been reported as protective of RA risk [Eyre et al., 2012], which
appears to be associated with lower benefit of anti-TNF. The rs12506688 is in the RB-J
gene which is a key upstream negative regulator of TNF-induced osteoclastogenesis.
β1 CIβ1 β2 CIβ2 β1 − β2 CIβ1−β2
Echo 0.02 [0.02, 0.18] -0.03 [-0.19, -0.03] 0.04 [0.08, 0.33]
rs2843401 -0.03 [-0.07, -0.02] 0 [-0.02, 0.03] -0.03 [-0.10, -0.01]
rs12506688 -0.08 [-0.18, -0.07] 0 [-0.03, 0.08] -0.08 [-0.23, -0.07]
rs8043085 0 [-0.03, 0.15] -0.05 [-0.21, -0.03] 0.05 [0.06, 0.29]
race black 0 [-0.30, 0.62] -0.02 [-0.70, 0.22] 0.02 [-0.10, 0.90]
prior CRP missing -0.17 [-0.7, -0.16] 0 [-0.23, 0.31] -0.17 [-1.24, 0.30]
Gold -0.01 [-0.13, -0.01] 0 [-0.11, 0.02] -0.01 [-0.12, 0.06]
SLE 0 [-0.07, 0.08] -0.16 [-0.34, -0.18] 0.16 [0.14, 0.40]
Table 5: Estimates of β1, β2 and β1 − β2 for the predictors of CRP along with their
95% CIs. All predictors not included the table received zero estimate for both β1 and
β2.
We obtained estimates of ∆new for the observed set of xnew. As shown in Figure 2(a),
the predicted ITE ranges from -1.3 to 0.6 with median -0.14. About 72% of the patients
in this population appear to benefit from combination therapy. We also obtained CIs for
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Fig. 2: (a) Histogram of the estimated ITE for the observed set of xnew where the vertical
line represents the median value; (b) point estimate and 95% CIs for 5 choices of xnew
where the x-axis indexes xᵀ
new
(β̂1 − β̂2).
a few examples of xnew, including (A) those with rs12506688 = 0, rs2843401 = 0, prior
CRP not missing, rs8043085 > 0, and ≥ 1 SLE mention; and (B) those with rs12506688
> 0, rs2843401 > 0, prior CRP missing, rs8043085 = 0, and no SLE mention. There are
three such patients in (A) (indexed by A1, A2, A3) and two in (B), (indexed by B1, B2).
The point estimates and their corresponding 95% CIs are shown in Figure 2(b). The
estimated ITEs were around -0.4 for A1-A3 with 95% CIs all below −0.2, suggesting
that adding anti-TNF is beneficial for these patients. On the contrary, anti-TNF may
even be detrimental for B1 and B2 whose estimated ITEs are 0.23 (95% CI: [0.058, 0.39])
and 0.30 (95% CI: [0.19, 0.41]), respectively. These results support prior findings that
the benefit of combination therapy is heterogeneous across patients.
8. Discussions
We introduced the HITS procedures for making inference about ITE with high-dimensional
covariates. Both the theoretical and numerical properties of the HITS testing and infer-
ence procedures are established. Unlike the high dimensional debiased methods proposed
in the literature, the proposed methods have the major advantage of not requiring the
covariate vector xnew to be sparse or of other specific forms. A key innovation of the pro-
posed procedure lies in the novel construction of the projection direction for debiased
where we imposed an additional constraint (8) when identifying the projection direc-
tion. We next discuss in more detail the importance of this step as well as an alternative
approach to further illustrate the challenges of statistical inference for dense loading.
The following proposition shows that the algorithm without (8) fails to correct the
bias of xᵀnewβ1 for a certain class of xnew.
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Proposition 2. The minimizer u˜1 in (6) is zero if either of the following conditions
on xnew is satisfied: (F1)
‖xnew‖2
‖xnew‖∞ ≥ 1λ1 ; (F2) The non-zero coordinates of xnew are of the
same order of magnitude and ‖xnew‖0 ≥ C
√
n1/log p for some positive constant C > 0.
Since ‖xnew‖2‖xnew‖∞ can be viewed as a measure of sparsity of xnew, both Conditions (F1) and
(F2) state that the optimization algorithm (6) fails to produce a non-vanishing projection
direction if the loading xnew is dense to certain degree. That is, without the additional
constraint (8), the projection direction u˜1 does not correct the bias of estimating x
ᵀ
newβ1.
We shall provide some geometric insights about Proposition 2. The feasible set for
constructing u˜ in (6) depends on both xnew and ‖xnew‖2. If the dimension p is large
and xnew ∈ Rp is dense, this feasible set is significantly enlarged in comparison to the
feasible set corresponding to the simpler case xnew = ei. As illustrated in Figure 3,
the larger and smaller dashed squares represent the feasible sets for a dense xnew and
xnew = ei, respectively. Since zero vector is contained in the feasible set for a dense
xnew, the optimizer in (6) is zero and the bias correction is not effective. With the the
additional constraint (8), even in the presence of dense xnew, the feasible set is largely
shrunk to be the solid parallelogram, as the intersection of the larger dashed square
and the parallel lines introduced by the constraint (8). Interestingly, the additional
constraint (8) simply restricts the feasible set from one additional direction determined
by xnew and automatically enables a unified inference procedure for an arbitrary xnew.
(0, 0)
Additional constraint
xnew = ei
Complex xnew
Fig. 3: The solid parallelogram corresponds to the feasible set of (7) and (8) for a dense
xnew while the large dashed triangle corresponds to that of (6); the small dashed square
corresponds to the feasible set of (6) for xnew = ei.
The current paper derives inference procedures for ITE based on high dimensional
outcome models. This allows us to include high dimensional confounders to overcome
treatment by indication bias frequently encountered in observational studies. The HITS
procedure is derived under a supervised linear regression setting. For EHR applications,
in addition to the labeled data with outcome variables observed, there are often also a
large amount of unlabeled data available where only the covariates are observed. It is
known that for certain inference problems, the unlabled data can be used to significantly
increase the inference accuracy [Cai and Guo, 2018c]. The problem of ITE inference in
the semi-supervised setting warrants future research.
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9. Proofs
In this section, we present the proof for the optimality results, Theorem 3 and Corollary
3 and also the proof for non-vanishing variance, Lemma 1. All other proofs are deferred
to Section C in the supplementary material.
9.1. Proof of Theorem 3 and Corollary 3
In the following theorem, we first introduce a general machinery for establishing the
detection boundary τadap(su, s,xnew) for the hypothesis testing problem (2).
Theorem 4 (Lower Bound for Detection Boundary). Suppose s ≤ su . min{p, nlog p}.
Re-order xnew such that |xnew,1| ≥ |xnew,2| ≥ · · · ≥ |xnew,p|. For any (q, L) satisfies q ≤ su
and L ≤ ‖xnew‖0, the adaptation detection boundary τadap(su, s,xnew) satisfies
τadap(su, s,xnew) ≥ τ∗ (50)
where
τ∗ = C
1√
n
·max

√√√√ s∑
j=1
x2new,j,
L∑
j=max{L−q+2,1}
|xnew,j|
√
(log (cL/q2))+
 . (51)
To establish the lower bounds in Theorem 3 and Corollary 3, we simply apply the
lower bound for the general detection boundary in (51) to the case of exact loadings.
Specifically, τ∗ is reduced to the following expression by taking L = ‖xnew‖0 and q =
min{su,
√‖xnew‖0},
τ∗ =
‖xnew‖∞√
n
·max
min{√s,√‖xnew‖0},min{su,√‖xnew‖0}
√√√√(log( c‖xnew‖0
min{su,
√‖xnew‖0}2
))
+
 .
(52)
For the case (E1), we have ‖xnew‖0 ≤ s2 ≤ s2u and τ∗  ‖xnew‖∞√n
√‖xnew‖0; hence the
lower bound (38) follows. For the case (E2), if γnew > 2γu, we have τ
∗  ‖xnew‖∞√
n
su
√
log p;
if γnew ≤ 2γu, we have τ∗  ‖xnew‖∞√n
√‖xnew‖0. Hence, the lower bounds in (39) follow.
By applying Corollary 1, we establish that the detection boundaries τadap(su, s,xnew)
in (40) and (42) are achieved by the hypothesis testing procedure φα defined in (15).
All the other detection boundaries will be achieved by the procedure φ(q, su) defined in
(74) in the supplement.
9.2. Proof of Lemma 1
The upper bound part of (19),
√
V ≤ C0‖xnew‖2
(
1√
n1
+ 1√n2
)
, follows from the following
lemma, which is the second high probability inequality of Lemma 4 established in Cai
and Guo [2017].
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Lemma 2. With probability larger than 1− p−c,∥∥∥Σ̂kûk − xnew∥∥∥∞ ≤ C‖xnew‖2
√
log p
nk
for k = 1, 2. (53)
By Lemma 2, Σ−11 xnew satisfies the constraints (7) and (8) and hence
V ≤ σ
2
1
n1
xᵀnewΣ
−1
1 Σ̂1Σ
−1
1 xnew +
σ22
n2
xᵀnewΣ
−1
2 Σ̂2Σ
−1
2 xnew. (54)
By Lemma 10 (specifically, the last high probability inequality) of Cai and Guo [2018c],
with probability larger than 1− p−c, we have∣∣∣∣∣xᵀnewΣ−11 Σ̂1Σ−11 xnewxᵀnewΣ−11 xnew − 1
∣∣∣∣∣ .
√
log p
n1
and
∣∣∣∣∣xᵀnewΣ−12 Σ̂2Σ−12 xnewxᵀnewΣ−12 xnew − 1
∣∣∣∣∣ .
√
log p
n2
(55)
Then we establish P
(√
V ≤ C0‖xnew‖2
(
1√
n1
+ 1√n2
))
≥ 1− p−c.
The proof of the lower bound part
√
V ≥ c0‖xnew‖2 is facilitated by the optimization
constraint (7). To be specific, we define a proof-facilitating optimization problem,
u¯1 = min
u∈Rp
uᵀΣ̂1u subject to
∣∣∣xᵀnewΣ̂1u− ‖xnew‖22∣∣∣ ≤ ‖xnew‖22λ1 (56)
Note that û1 satisfies the feasible set of (56) and hence
ûᵀ1Σ̂1û1 ≥ u¯ᵀ1Σ̂1u¯1 ≥ u¯ᵀ1Σ̂1u¯1 + t
(
(1− λ1)‖xnew‖22 − xᵀnewΣ̂1u¯1
)
for any t ≥ 0,
(57)
where the last inequality follows from the constraint of (56). Note that for any given
t ≥ 0,
u¯ᵀ1Σ̂1u¯1 + t
(
(1− λ1)‖xnew‖22 − xᵀnewΣ̂1u¯1
)
≥ min
u∈Rp
uᵀΣ̂1u + t
(
(1− λ1)‖xnew‖22 − xᵀnewΣ̂1u
)
.
(58)
By solving the minimization problem of the right hand side of (58), we have the minimizer
u∗ satisfies Σ̂1u∗ = t2Σ̂1xnew and hence the minimum of the right hand side of (58) is
− t
2
4
xᵀnewΣ̂1xnew + t(1− λ1)‖xnew‖22.
Combined with (57) and (58), we have
ûᵀ1Σ̂1û1 ≥ max
t≥0
[
− t
2
4
xᵀnewΣ̂1xnew + t(1− λ1)‖xnew‖22
]
. (59)
For t∗ = 2 (1−λ1)‖xnew‖
2
2
xnᵀewΣ̂1xnew
> 0, the minimum of the right hand side of (59) is achieved and
hence
ûᵀ1Σ̂1û1 ≥
(1− λ1)2‖xnew‖42
xᵀnewΣ̂1xnew
. (60)
30 Cai, Cai & Guo
By Lemma 10 (specifically, the last high probability inequality) of Cai and Guo [2018c],
with probability larger than 1 − p−c, we have
∣∣∣xnᵀewΣ̂1xnewxnᵀewΣ1xnew − 1∣∣∣ . √log p/n1 and hence
ûᵀ1Σ̂1û1 ≥ c‖xnew‖22. Similarly, we can establish ûᵀ2Σ̂2û2 ≥ c‖xnew‖22 and hence
P
(√
V ≥ c0‖xnew‖2
(
1√
n1
+
1√
n2
))
≥ 1− p−c. (61)
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A. Detection Boundary for Decaying Loading
In the following, we consider the optimality result about decaying loading. Specifically,
we calibrate the i-th largest element xnew,(i) by the decaying rate parameter δ as defined
in (37). A larger value of δ means that the loading decays faster; for the case δ = 0, the
loading is not decaying at all.
Theorem 5. Suppose that s ≤ su . nlog p . We calibrate s, su and the decaying of xnew
by γ, γu and δ, respectively, as defined in (35) and (37).
(D1) If xnew is a fast decaying loading with δ ≥ 12 , then
τadap(su, s,xnew) &
1√
n
· (1 +
√
log s · 1(δ = 1
2
)) (62)
(D2) If xnew is a slow decaying loading with 0 ≤ δ < 12 , then
τadap(su, s,xnew) &
cp
s1−2δu√
n
(log p)
1
2
−δ if γu < 12√
p1−2δ
n if γu ≥ 12
(63)
where cp =
√
log(log p)
log p .
Similar to the exact sparse loading in Theorem 3, the detection lower bounds in the
above Theorem can be attained under regularity conditions. The following corollary
presents the matched upper bound for the detection boundaries established in Theorem
5 over certain regimes.
Corollary 6. Suppose that s ≤ su .
√
n
log p .
(D1) If xnew is a fast decaying loading with δ ≥ 12 , then
τadap(su, s,xnew)  τmini(s,xnew)  ‖xnew‖2√
n
(64)
In particular, for δ = 12 , the detection boundary holds if γ > 0; otherwise the
detection boundary holds up to a
√
log p
log s factor.
(D2) If xnew is a slow decaying loading with 0 ≤ δ < 12 , then the minimaxity detection
boundary and adaptive detection boundary hold up to a
√
log p order
(D2-a) If the true sparsity s and the knowledge of su satisfies satisfies γ < γu ≤ 12 ,
then
τadap(su, s,xnew)  s
1−2δ
u√
n
(log p)
1
2
−δ  τmini(s,xnew)  s
1−2δ
√
n
(log p)
1
2
−δ .
(65)
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(D2-b) If the true sparsity s and the knowledge of su satisfies γ <
1
2 ≤ γu, then
τadap(su, s,xnew) 
√
p1−2δ
n
 τmini(s,xnew)  s
1−2δ
√
n
(log p)
1
2
−δ . (66)
(D2-c) If the true sparsity s and the knowledge of su satisfies
1
2 ≤ γ < γu, then
τadap(su, s,xnew)  τmini(s,xnew) 
√
p1−2δ
n
. (67)
We will provide some remarks for the above corollary. As an analogy to the ex-
act sparse loading, (D1), (D2-a) and (D2-b) correspond to (E1), (E2-a) and (E2-b),
respectively.
(D1) This corresponds to a large class of fast decaying loadings. in this case, even without
the exact information about the sparsity level, we can conduct the hypothesis
testing procedure as well as we know the exact sparsity level.
(D2) For the case of slowly decaying loading xnew, we first discuss the following two cases,
(D2-a) This is similar to (E2-a), where the prior knowledge of sparsity su is relatively
precise. We can use the sparsity level su to construct a testing procedure
matching the adaptive detection boundary. See the proof of Corollary 6 for
details.
(D2-b) This is similar to (E2-b), where the prior knowledge of sparsity su is rough.
For such a case, the proposed testing procedure φα defined in (15) achieves
the adaptive detection boundary.
Although the decaying loading shares some similarity with the exact sparse loading, there
still exist significant distinctions in terms of the exact detection boundary. Interestingly,
there exists an additional case (D2-c), which correspond to the case that the true sparsity
itself is relatively dense. In this case, although the true sparsity level is high and the
knowledge of sparsity is not available, the hypothesis testing problem itself is adaptive,
which means, without any knowledge on the true sparsity level, we can conduct the
hypothesis testing problem as well as the case of known sparsity.
We conclude this section by establishing a uniform optimality result of the proposed
testing procedure φα in (15) over the decaying loading xnew, which parallels the corollary
4 in the main paper for the case of exact loading,
Corollary 7. Suppose that s ≤ su .
√
n
log p and γu ≥ 12 . Then the testing procedure
φα in (15) achieves the adaptive detection boundary τadap(su, s,xnew)  ‖xnew‖2√n for any
xnew satisfying (37).
The above Corollary states that, in absence of accurate sparsity information, the
proposed procedure φα is an adaptive optimal test for all decaying loadings xnew.
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B. Sparsity-assisted Hypothesis Testing Procedure
In this section, we consider the setting that there is additional information on the sparsity
and present the method of constructing confidence interval for ∆new and conducting
hypothesis testing for (2) with incorporating the given sparsity information. Without
loss of generality, we can assume the loading xnew is ordered as follows,
|xnew,1| ≥ |xnew,2| ≥ · · · ≥ |xnew,p|. (68)
For k = 1, 2, we define β˜k,j to be the de-biased estimator introduced by Javanmard and
Montanari [2014] with the corresponding covariance matrix of β˜k,· ∈ Rp as V̂ar
k
. Define
d = β1 − β2. For 1 ≤ j ≤ p, we introduce the hard-thresholding estimator d̂j as
d̂j =
(
β˜1,j − β˜2,j
)
× 1

∣∣∣∣∣∣ β˜1,j − β˜2,j√V̂ar1j,j + V̂ar2j,j
∣∣∣∣∣∣ ≥√2.01 log p

Define the vector ξ as a sparsified version of xnew,
ξj = xnew,j for 1 ≤ j ≤ q, ξj = 0 for q + 1 ≤ j ≤ p, (69)
and also
ξ̂j = 0 for 1 ≤ j ≤ q, ξ̂j = xnew,j
√
V̂ar
1
j,j + V̂ar
2
j,j for q + 1 ≤ j ≤ p, (70)
where q is an integer to be specified later. We define the estimator ξ̂ᵀd as in (11) with
xnew replaced with the sparsified loading ξ. In particular, the projection directions uˇk for
k = 1, 2 are constructed as
uˇk = arg min
u∈Rp
uᵀΣ̂ku subject to
∥∥∥Σ̂ku− ξ∥∥∥∞ ≤ ‖ξ‖2λk∣∣∣ξᵀΣ̂ku− ‖ξ‖22∣∣∣ ≤ ‖ξ‖22λk,
where λk 
√
log p/nk. Define the sum S(su) =
∑su
j=1
∣∣∣ξ̂(j)∣∣∣ , where ξ̂(j) as the j-th
largest absolute value of ξ̂. We propose the following estimator
∆ˇnew = ξ̂ᵀd +
p∑
j=q+1
xnew,jd̂j . (71)
We construct the CI as
CI(q, su) =
(
∆ˇnew − ρα/2(q, su), ∆ˇnew + ρα/2(q, su)
)
(72)
where ρα/2(q, su) = zα/2
√
V˜ + S(su)
√
2.01 log p, with V˜ defined as
V˜ =
σ̂21
n1
uˇᵀ1Σ̂1uˇ1 +
σ̂22
n2
uˇᵀ2Σ̂2uˇ2. (73)
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We propose the following decision rule,
φ(q, su) = 1
(
∆ˇnew − ρα(q, su) > 0
)
. (74)
where ρα(q, su) = zα
√
V˜ + S(su)
√
2.01 log p,
For the estimator defined in (71), we have the following error decomposition,
∆ˇnew −∆new = ξ̂ᵀd− ξᵀd +
p∑
j=q+1
xnew,j(d̂j − dj), (75)
It follows from Theorem 2 that
ξ̂ᵀd− ξᵀd√
V˜
→ N(0, 1) (76)
In addition, with probability larger than 1− p−c,∣∣∣∣∣∣
p∑
j=q+1
xnew,j(d̂j − dj)
∣∣∣∣∣∣ ≤ S(su)√2.01 log p (77)
Combining (75), (76) and (77), we establish the coverage property of the confidence in-
terval CI(q, su) proposed in (72) and also control the type I error of the testing procedure
φ(q, su) defined in (74). It remains to control the length of ρα(q, su). We focus on the
decaying loading |xnew,j|  j−δ for 0 ≤ δ < 12 . Following from (97), we have√
V˜  ‖ξ‖2 .
√√√√ q∑
j=1
|xnew,j|2
√
1
n1
+
1
n2
. q 12−δ
√
1
n1
+
1
n2
(78)
and
S(su) =
su∑
j=1
∣∣∣ξ̂(j)∣∣∣ .√ 1n1 + 1n2
q+su∑
j=q+1
|xnew,i| . su · (q + csu)−δ
√
1
n1
+
1
n2
(79)
We take q = bs2u log pc for both decaying loading and the exact loading and have
|ρα(q, su)| . (su2 log p) 12−δ
√
1
n1
+
1
n2
(80)
For the exact loading, we can also take q = 0.
C. Additional Proofs
We present the proof of Theorem 4 in Section C.1; we present the proof of Theorem 5
and Corollary 6 in Section C.2; we present the proofs of Theorems 1 and 2 in Section C.3;
we present the proof of Proposition 1 in Section C.4; we present the proof of Corollaries
1 and 2 in Section C.5; we present the proof of Proposition 2 in Section C.6.
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C.1. Proof of Theorem 4
Suppose that we observe a random variable Z which has a distribution Pθ where the
parameter θ belongs to the parameter space H. Let pii denote the prior distribution
supported on the parameter space Hi for i = 0, 1. Let fpii (z) denote the density function
of the marginal distribution of Z with the prior pii on Hi for i = 0, 1. More specifically,
fpii (z) =
∫
fθ (z)pii (θ) dθ, for i = 0, 1. Denote by Ppii the marginal distribution of Z
with the prior pii on Hi for i = 0, 1. For any function g, we write EpiH0 (g (Z)) for the
expectation of g (Z) with respect to the marginal distribution of Z with the prior piH0
on H0. We define the χ2 distance between two density functions f1 and f0 by
χ2(f1, f0) =
∫
(f1(z)− f0(z))2
f0(z)
dz =
∫
f21 (z)
f0(z)
dz − 1 (81)
and the total variation distance by L1(f1, f0) =
∫ |f1(z)− f0(z)| dz. It is well known
that
L1(f1, f0) ≤
√
χ2(f1, f0). (82)
Lemma 3. Suppose that pii is a prior on the parameter space Fi for i = 0, 1, then we
have
inf
θ∈F1
Eθφ ≤ L1 (fpi1 , fpi0) + sup
θ∈F0
Eθφ (83)
In addition, suppose that L1 (fpi1 , fpi0) < 1 − α − η for 0 < α < 12 , F0 ⊂ H0(su) andF1 ⊂ H1(s, τ), then
τadap(su, s,xnew) ≥ min
θ0∈F0,θ1∈F1
|T(θ0)− T(θ1)| . (84)
Proof of Lemma 3 It follows from the definition of L1(f1, f0) that
Epi1φ− Epi0φ ≤ L1 (fpi1 , fpi0) . (85)
Then (83) follows from
inf
θ∈F1
Eθφ ≤ Epi1φ ≤ L1 (fpi1 , fpi0) + Epi0φ ≤ L1 (fpi1 , fpi0) + sup
θ∈F0
Eθφ,
where the first and last inequalities follows from the definition of inf and sup and the
second inequality follows from (85). The lower bound in (84) follows from the definition
of τadap(su, s,xnew) and the fact that
ω(s, τ, φ) ≤ inf
θ∈F1
Eθφ ≤ L1 (fpi1 , fpi0) + sup
θ∈F0
Eθφ ≤ 1− η.
To establish the lower bound results, we divide the whole proof into two parts, where
the first proof depends on the location permutation and the second proof does not de-
pend on this.
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Permuted Location Lower Bound We first establish the following lower bound
through permuting the locations of non-zero coefficients,
τadap(su, s,xnew) ≥ 1√
n
L∑
j=max{L−q+2,1}
|xnew,j|
√
(log (cL/q2))+. (86)
For this case, we assume that q ≤ √cL; otherwise the lower bound in (86) is trivial.
To simplify the notation of the proof, we fix β2 = 0 and denote β1 = η. In addition,
we set Σ1 = Σ2 = I and σ2 = 1. Without loss of generality, we set xnew,i ≥ 0 and
xnew,i ≥ xnew,i+1. By applying Lemma 3, we need to construct two parameters spaces
F0 and F1 with considering the following three perspectives,
(a) F0 ⊂ H0(su) and F1 ⊂ H1(s, τ).
(b) to constrain the distribution distance L1 (fpi1 , fpi0)
(c) to maximize the functional distance minθ0∈F0,θ1∈F1 |T(θ0)− T(θ1)|
To establish the lower bound (86), we construct the following parameter spaces,
F0 =
{
θ =
(
η, 1, I
0, 1, I
)
: η1 = ρ ·
∑L
j=L−q+2 xnew,j
xnew,1
, ‖η−1‖0 = q − 1,ηj ∈ {0,−ρ} for 2 ≤ j ≤ L
}
F1 =
{
θ =
(
η, 1, I
0, 1, I
)
: η1 = ρ ·
∑L
j=L−q+2 xnew,j
xnew,1
,η−1 = 0
}
(87)
For θ ∈ F0, we have ∆new = ρ ·
(∑L
j=L−q+2 xnew,j −
∑
j∈supp(η−1) xnew,j
)
≤ 0, which is
due to the definition of supp(η−1); For θ ∈ F1, we have ∆new = ρ ·
∑L
j=L−q+2 xnew,j ≥ 0.
Hence, we have shown that
F0 ⊂ H0(su) and F1 ⊂ H1(s, τ) for τ = ρ ·
L∑
j=L−q+2
xnew,j (88)
To establish the distributional difference, we introduce pi0 to be the uniform prior on the
parameter space F0 and pi1 to denote the mass point prior on the parameter space F1.
Since L1 distance is symmetric, we have
L1(fpi1 , fpi0) ≤
√
χ2(fpi0 , fpi1). (89)
As a remarkable difference from the typical lower bound construction, the null parameter
space F0 is composite but the alternate parameter space F1 is simple. We use the
symmetric property of the L1 distance to control the distributional difference between
this composite null and simple alternative in (89). We take ρ = 12
√
2 log[(L−1)/(q−1)2]
n .
By Lemma 3 and Lemma 4 in Cai and Guo [2018b], we rephrase (3.33) in Cai and Guo
[2018b] as
χ2(fpi0 , fpi1) + 1 ≤ exp
(
(q − 1)2
L− q
)(
1 +
1√
L− 1
)q−1
≤ exp
(
(q − 1)2
L− q +
q − 1√
L− 1
)
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The above inequality is further upper bounded by exp(12w
2 + w) for w = q√
L
. Un-
der the condition q√
L
≤ c, we have L1(fpi1 , fpi0) ≤
√
exp(12c
2 + c)− 1. By taking c =√
1 + 2 log[c20 + 1] − 1, we have L1(fpi1 , fpi0) < c0. Then it suffices to control the func-
tional difference minθ0∈F0,θ1∈F1 |T(θ0)− T(θ1)|, where T = ∆new and hence we have
min
θ0∈F0,θ1∈F1
|T(θ0)− T(θ1)| &
√
2 log[L/q2]
n
·
L∑
j=L−q+2
xnew,j (90)
Fixed Location Lower Bound We will establish the following lower bound,
τadap(su, s,xnew) ≥ 1√
n
·
√√√√ s∑
j=1
x2new,j. (91)
In this case, we do not perturb the location of non-zeros in constructing the null and
alternative space but only perturb the coefficients corresponding to s-largest coefficients.
To simplify the notation of the proof, we fix β2 = 0 and denote β1 = η. In addition, we
set Σ1 = Σ2 = I and σ2 = 1. Without loss of generality, we set xnew,i ≥ 0 and xnew,i ≥
xnew,i+1. To establish the lower bound (86), we construct the following parameter space,
F0 =
{
θ =
(
0, 1, I
0, 1, I
)}
F1 =
θ =
(
η, 1, I
0, 1, I
)
: ηj = ρ · xnew,j√∑s
j=1 x
2
new,j
for 1 ≤ j ≤ s

(92)
For θ ∈ F0, we have ∆new = 0; For θ ∈ F1, we have ∆new = ρ ·
√∑s
j=1 x
2
new,j ≥ 0.
Hence, we have shown that
F0 ⊂ H0(su) and F1 ⊂ H1(s, τ) for τ = ρ ·
√√√√ s∑
j=1
x2new,j (93)
Let pi0 and pi1 denote the point mass prior over the parameter space F0 and F1, respec-
tively. It follows from (7.25) in Cai and Guo [2017] that
χ2(fpi1 , fpi0) ≤ exp
(
2nρ2
)− 1 (94)
By taking ρ =
√
log(1+c20)
2n , we have L1(fpi1 , fpi0) ≤ c0. Then it suffices to control the
functional difference minθ0∈F0,θ1∈F1 |T(θ0)− T(θ1)|, where T = ∆new and hence we have
min
θ0∈F0,θ1∈F1
|T(θ0)− T(θ1)| & 1√
n
·
√√√√ s∑
j=1
x2new,j. (95)
42 Cai, Cai & Guo
C.2. Proof of Theorem 5 and Corollary 6
The lower bound is an application of the general detection boundary (51), which is
translated to the following lower bound,
τ ≤ τ∗ = 1√
n
·max

√√√√ s∑
j=1
j−2δ,
L∑
j=max{L−q+2,1}
j−δ
√
(log (cL/q2))+
 . (96)
We also need the following fact, for integers l1 > 2 and l2 > l1∫ l2+1
l1
x−δdx ≤
l2∑
j=l1
j−δ ≤
∫ l2
l1−1
x−δdx
Hence, we further have
l2∑
j=l1
j−δ ∈

1
δ−1 [(l1 − 1)1−δ − l1−δ2 , l1−δ1 − (l2 + 1)1−δ] for δ > 1
[log l2+1l1 , log
l2
l1−1 ] for δ = 1
1
1−δ [(l2 + 1)
1−δ − l1−δ1 , l1−δ2 − (l1 − 1)1−δ] for δ < 1
(97)
For the case (D1), we first consider the case 2δ > 1 and hence
∑s
j=1 j
−2δ = 1 +∑s
j=2 j
−2δ  1; for the case 2δ = 1, we have ∑sj=1 j−2δ = 1 + ∑sj=2 j−2δ  log s;
Hence, the lower bound (62) follows.
For the case (D2), we first consider γu ≥ 12 , we take q =
√
p in (96) and have
p∑
j=max{p−q+2,1}
j−δ ≥ 1
1− δ
(
(p+ 1)1−δ − (p−√p− 2)1−δ
)
 (p− c√p)−δ√p  p 12−δ.
(98)
For the case γu <
1
2 , we take L = s
2
u log p, then we have
L∑
j=max{L−su+2,1}
j−δ ≥ 1
1− δ
(
(L+ 1)1−δ − (L− su + 2)1−δ
)
 (L−csu)−δsu  s1−2δu (log p)−δ.
Hence we have
L∑
j=max{L−su+2,1}
j−δ
√
(log (cL/s2u))+ ≥ s1−2δu (log p)
1
2
−δ
√
log(log p)
log p
.
Combined with (98), we establish the lower bound (63). Since
‖xnew‖2 =
√√√√ p∑
j=1
j−2δ 

1 for δ > 1/2√
log p for δ = 1/2
p
1
2
−δ for δ < 1/2
we apply Corollary 1 to establish the upper bounds and show that the detection bound-
aries τadap(su, s,xnew) in (64), (66) and (67) are achieved by the hypothesis testing
procedure φα defined in (15). In addition, the detection boundaries τmini(s,xnew) and
τadap(su, s,xnew) in (65) and τmini(s,xnew) in (66) are achieved by the hypothesis testing
procedure introduced in (74).
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C.3. Proof of Theorems 1 and 2
By combining the error decompositions for k = 1 and k = 2 in (16), we have
x̂ᵀnewβ1 − x̂ᵀnewβ2 − xᵀnew (β1 − β2) = ûᵀ1
1
n
n∑
i=1
X1,i1,i − ûᵀ2
1
n
n∑
i=1
X2,i2,i
+
(
Σ̂1û1 − xnew
)ᵀ
(β̂1 − β1)−
(
Σ̂2û2 − xnew
)ᵀ (
β̂2 − β2
) (99)
By Ho¨lder’s inequality, for k = 1, 2, we have∣∣∣(Σ̂kûk − xnew)ᵀ (β̂k − βk)∣∣∣ ≤ ∥∥∥Σ̂kûk − xnew∥∥∥∞·‖β̂k−βk‖1 . ‖xnew‖2
√
log p
nk
·‖βk‖0
√
log p
nk
,
where the second inequality follows from the optimization constraint (7) and the condi-
tion (B1). Hence, we establish that, with probability larger than 1− g(n1, n2),∣∣∣(Σ̂1û1 − xnew)ᵀ (β̂1 − β1)− (Σ̂2û2 − xnew)ᵀ (β̂2 − β2)∣∣∣
. ‖xnew‖2
(‖β1‖0 log p
n1
+
‖β2‖0 log p
n2
)
.
(100)
Note that
E·|X
(
ûᵀ1
1
n1
n1∑
i=1
X1,i1,i − ûᵀ2
1
n2
n2∑
i=1
X2,i2,i
)2
= V, (101)
where V is defined in (12). By (19), with probability larger than 1− p−c − 1t2 , then∣∣∣∣∣ûᵀ1 1n1
n1∑
i=1
X1,i1,i − ûᵀ2
1
n2
n2∑
i=1
X2,i2,i
∣∣∣∣∣ . t‖xnew‖2
(
1√
n1
+
1√
n2
)
(102)
Combing (100) and (102), we establish Theorem 1.
By assuming the condition (A3), we show that conditioning on X, ûᵀ1
1
n1
∑n1
i=1 X1,i1,i −
ûᵀ2
1
n2
∑n2
i=1 X2,i2,i ∼ N(0,V) where V is defined in (12). After normalization, we have
1√
V
(
ûᵀ1
1
n1
n1∑
i=1
X1,i1,i − ûᵀ2
1
n2
n2∑
i=1
X2,i2,i
)
| X ∼ N(0, 1)
and then after integrating with respect to X, we have
1√
V
(
ûᵀ1
1
n1
n1∑
i=1
X1,i1,i − ûᵀ2
1
n2
n2∑
i=1
X2,i2,i
)
∼ N(0, 1) (103)
Combing (100) with (19), we show that with probability larger than 1− p−c− g(n1, n2),
1√
V
∣∣∣(Σ̂1û1 − xnew)ᵀ (β̂1 − β1)− (Σ̂2û2 − xnew)ᵀ (β̂2 − β2)∣∣∣ ≤ ‖β1‖0 log p√
n1
+
‖β2‖0 log p√
n2
.
Together with (103), we establish Theorem 2.
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C.4. Proof of Proposition 1
In the following proof, we omit the index k to simply the notation, that is, u = uk,
Σ̂ = Σ̂k and λ = λk. We introduce the corresponding Lagrange function,
L(u, τ, η, τ0, η0) = u
ᵀΣ̂u + τᵀ
(
Σ̂u− xnew − ‖xnew‖2λ1
)
+ ηᵀ
(
xnew − Σ̂u− ‖xnew‖2λ1
)
+ τ0
(
xᵀnew
‖xnew‖2 Σ̂u− (1 + λ)‖xnew‖2
)
+ η0
(
(1− λ)‖xnew‖2 − x
ᵀ
new
‖xnew‖2 Σ̂u
)
(104)
where τ ∈ Rp, η ∈ Rp and {τi, ηi}0≤i≤p are positive constants. Then we derive the dual
function g(τ, η, τ0, η0) = arg minu L(u, τ, η, τ0, η0). By taking the first order-derivative of
L(u, τ, η, τ0, η0), we establish that the minimizer u
∗ of L(u, τ, η, τ0, η0) satisfies
2Σ̂u∗ + Σ̂
[
(τ − η) + (τ0 − η0) xnew‖xnew‖2
]
= 0. (105)
By introducing γ = τ − η and γ0 = τ0 − η0, we have the expression of L(u∗, τ, η, τ0, η0)
as
g(γ, η, γ0, η0) = −1
4
[
γ + γ0
xnew
‖xnew‖2
]ᵀ
Σ̂
[
γ + γ0
xnew
‖xnew‖2
]
− xᵀnewγ − ‖xnew‖2λ1ᵀ(γ + 2η)
− ‖xnew‖2γ0 − λn‖xnew‖2(γ0 + 2η0), where ηi ≥ −γi and ηi ≥ 0 for 0 ≤ i ≤ p
The computation of the maximum over η0 and {ηi}1≤i≤p is based on the following obser-
vation, if γi ≥ 0, then maxηi≥max{0,−γi} γi + 2ηi = γi; if γi < 0, then maxηi≥max{0,−γi} γi + 2ηi =
−γi; Hence,
max
ηi≥max{0,−γi}
γi + 2ηi = |γi| . (106)
By applying (106), we establish
max
η,η0
g(γ, η, γ0, η0) = −1
4
[
γ + γ0
xnew
‖xnew‖2
]ᵀ
Σ̂
[
γ + γ0
xnew
‖xnew‖2
]
− xᵀnew
(
γ + γ0
xnew
‖xnew‖2
)
− λ‖xnew‖2 (|γ0|+ ‖γ‖1)
(107)
Then it is equivalent to solve the dual problem defined in (47). By (105), we establish
(46).
C.5. Proof of Corollaries 1 and 2
Note that
∣∣∣ V̂V − 1∣∣∣ ≤ ∑2j=1 ∣∣∣ σ̂2jσ2j − 1∣∣∣ and hence V̂V p→ 1 follows from the condition (B2).
Together with Theorem 2, we establish these two corollaries.
C.6. Proof of Proposition 2
Under the condition (F1), the projection u = 0 belongs to the feasible set in (6) and
hence the minimizer u˜1 of (6) is zero since Σ̂1 is semi-positive-definite matrix.
If the non-zero coordinates of the loading xnew are of the same order of magnitude,
we have ‖xnew‖2  ‖xnew‖0‖xnew‖∞. Then the condition ‖xnew‖0 ≥ C
√
n1/log p will
imply the condition (F1).
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D. Additional Simulation Results
In this session, we present additional simulation results for the decaying loading case,
where xnew is generated as,
xnew,j = Ratio · j−δ,
where δ ∈ {0, 0.1, 0.25, 0.5} and Ratio ∈ {0.25, 0.375, 0.5}. The results are reported in
Table 6 and the observation is consistent with that reported in Section 6.2 in the main
paper.
ERR Coverage Len HITS Lasso Deb
δ Ratio n HITS Deb HITS Deb HITS Deb RM Bias SE RM Bias SE RM Bias SE
0
0.25
200 0.86 0.79 0.96 0.95 1.54 1.75 0.39 0.03 0.39 0.20 0.13 0.15 0.45 0.01 0.45
300 0.99 0.95 0.96 0.97 1.11 1.39 0.26 0.03 0.26 0.16 0.11 0.12 0.33 0.01 0.33
400 1.00 0.98 0.96 0.96 1.00 1.19 0.25 0.02 0.25 0.13 0.09 0.10 0.30 0.01 0.30
0.375
200 0.93 0.90 0.96 0.96 2.29 2.60 0.55 0.04 0.55 0.27 0.21 0.18 0.62 0.02 0.62
300 0.99 0.96 0.95 0.94 1.63 2.06 0.42 0.04 0.42 0.22 0.17 0.15 0.53 0.01 0.53
400 1.00 0.99 0.95 0.95 1.46 1.76 0.35 0.01 0.35 0.19 0.14 0.12 0.43 0.05 0.43
0.5
200 0.98 0.93 0.97 0.97 3.00 3.45 0.69 0.05 0.69 0.35 0.28 0.21 0.83 0.05 0.83
300 1.00 1.00 0.97 0.97 2.17 2.74 0.51 0.09 0.50 0.29 0.23 0.17 0.63 0.03 0.63
400 1.00 1.00 0.95 0.94 1.94 2.33 0.50 0.05 0.50 0.25 0.20 0.15 0.61 0.00 0.61
0.1
0.25
200 0.97 0.96 0.95 0.95 1.02 1.09 0.25 0.04 0.25 0.18 0.13 0.12 0.27 0.00 0.27
300 1.00 0.99 0.95 0.96 0.70 0.87 0.18 0.03 0.18 0.15 0.10 0.10 0.21 0.00 0.21
400 1.00 1.00 0.96 0.96 0.65 0.75 0.16 0.03 0.16 0.12 0.09 0.08 0.19 0.00 0.19
0.375
200 0.99 0.99 0.95 0.97 1.43 1.59 0.36 0.06 0.35 0.25 0.20 0.16 0.39 0.00 0.39
300 1.00 1.00 0.96 0.98 1.01 1.26 0.24 0.05 0.23 0.20 0.17 0.12 0.29 0.00 0.29
400 1.00 1.00 0.95 0.96 0.91 1.08 0.23 0.02 0.22 0.17 0.14 0.10 0.26 0.02 0.26
0.5
200 1.00 1.00 0.97 0.97 1.87 2.09 0.44 0.05 0.44 0.30 0.26 0.17 0.50 0.02 0.50
300 1.00 1.00 0.96 0.97 1.32 1.66 0.32 0.07 0.32 0.26 0.22 0.14 0.40 0.00 0.40
400 1.00 1.00 0.96 0.94 1.20 1.42 0.30 0.05 0.29 0.22 0.19 0.12 0.35 0.00 0.35
0.25
0.25
200 0.99 1.00 0.93 0.92 0.59 0.62 0.16 0.02 0.16 0.17 0.11 0.13 0.17 0.01 0.17
300 1.00 1.00 0.95 0.95 0.44 0.50 0.12 0.03 0.11 0.14 0.10 0.09 0.13 0.00 0.13
400 1.00 1.00 0.94 0.95 0.39 0.45 0.11 0.02 0.10 0.12 0.09 0.08 0.12 0.01 0.12
0.375
200 1.00 1.00 0.96 0.96 0.81 0.84 0.21 0.05 0.20 0.22 0.18 0.12 0.21 0.00 0.21
300 1.00 1.00 0.95 0.96 0.56 0.68 0.14 0.04 0.14 0.18 0.15 0.10 0.16 0.00 0.16
400 1.00 1.00 0.96 0.96 0.52 0.59 0.13 0.02 0.13 0.15 0.13 0.09 0.15 0.00 0.15
0.5
200 1.00 1.00 0.96 0.96 1.01 1.07 0.25 0.05 0.25 0.27 0.24 0.13 0.27 0.02 0.27
300 1.00 1.00 0.91 0.94 0.69 0.86 0.19 0.05 0.19 0.22 0.19 0.12 0.22 0.01 0.22
400 1.00 1.00 0.93 0.95 0.64 0.74 0.17 0.03 0.17 0.19 0.16 0.10 0.19 0.00 0.19
0.5
0.25
200 0.96 0.99 0.94 0.91 0.48 0.41 0.13 0.02 0.13 0.15 0.10 0.11 0.12 0.00 0.12
300 1.00 1.00 0.89 0.91 0.34 0.35 0.10 0.02 0.10 0.13 0.09 0.09 0.10 0.00 0.10
400 1.00 1.00 0.93 0.92 0.31 0.32 0.09 0.01 0.09 0.11 0.07 0.08 0.09 0.00 0.09
0.375
200 1.00 1.00 0.91 0.92 0.49 0.46 0.14 0.03 0.13 0.20 0.16 0.12 0.13 0.00 0.13
300 1.00 1.00 0.94 0.95 0.38 0.39 0.11 0.01 0.10 0.15 0.12 0.10 0.11 0.01 0.11
400 1.00 1.00 0.92 0.95 0.33 0.36 0.09 0.02 0.09 0.13 0.11 0.08 0.09 0.00 0.09
0.5
200 1.00 1.00 0.92 0.94 0.53 0.54 0.15 0.04 0.14 0.24 0.21 0.13 0.14 0.00 0.14
300 1.00 1.00 0.94 0.94 0.42 0.45 0.11 0.02 0.11 0.18 0.15 0.10 0.12 0.01 0.12
400 1.00 1.00 0.92 0.93 0.36 0.40 0.10 0.02 0.10 0.17 0.14 0.09 0.11 0.00 0.11
Table 6: Performance of the HITS hypothesis testing, in comparison with the plug-in
Debiased Estimator (“Deb”), with respect to empirical rejection rate (ERR) as well
as the empirical coverage (Coverage) and length (Len) of the CIs under the decaying
loading xnew,j = Ratio ∗ j−δ. Reported also are the RM, bias and the standard error
(SE) of the HITS estimator compared to the plug-in LASSO estimator (“Lasso”) and
the plug-in Debiased Estimator (“Deb”).
